Jurisprudence Exam Drug Schedules...Jurisprudence Exam . Drug Schedules *DO NOT WRITE OR MAKE ANY...

59
Jurisprudence Exam Drug Schedules *DO NOT WRITE OR MAKE ANY MARKS ON THE DRUG SCHEDULE*

Transcript of Jurisprudence Exam Drug Schedules...Jurisprudence Exam . Drug Schedules *DO NOT WRITE OR MAKE ANY...

Jurisprudence Exam

Drug Schedules *DO NOT WRITE OR MAKE ANY MARKS ON THE DRUG SCHEDULE*

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 1/40

1 Abacavir and its salts1 Abatacept1 Abciximab1 Acamprosate and its salts1 Acarbose and its derivatives1 Acebutolol and its salts1 Acepromazine and its saltsV

1 Acetaminophen, when recommended for administration by intravenous injection3 Acetaminophen (in sustained-release formulations containing greater than 650 mg per unit or

in package sizes greater than 50 units)1 AcetanilideV

2 Acetarsol1 Acetazolamide1 Acetohexamide1 Acetylcarbromal1 Acetylcholine Chloride2 Acetylcysteine1 Acetylsalicylic acid and its salts (in oral preparations containing 80 mg or less per dosage unit

in containers with more than 24 dosage units per container)2 Acetylsalicylic acid and its salts (in oral preparations containing 80 mg or less per dosage unit

in child-resistant containers with 24 or less dosage units per container or rectal preparationscontaining 150 mg or less per dosage unit)

3 Acetylsalicylic acid and its salts (in products intended for oral use by adults in strengths of81 mg per dosage unit and 650 mg or greater per dosage unit and in rectal preparationscontaining more than 150 mg per dosage unit)

1 Acitretin and its salts and derivatives1 Aconiazide and its salts1 Acyclovir and its salts1 Adalimumab1 Adapalene and its salts and derivatives1 Adefovir and its salts and derivatives1 Adenosine or its salts when sold or recommended for administration by intravenous injection2 Adiphene and its salts for parenteral use1 Adrenocortical hormones and their salts and derivativesV, including but not limited to

betamethasone dipropionate, betamethasone phosphate, betamethasone sodium,betamethasone valerate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasoneacetate, dexamethasone phosphate, dexamethasone sodium, difluprednate, fludrocortisoneacetate, flunisolide, fluticasone furoate, fluticasone propionate, hydrocortisone aceponate,hydrocortisone acetate, hydrocortisone sodium, methylprednisolone acetate,methylprednisolone, methylprednisolone sodium, methylprednisolone succinate, mometasonefuroate, prednisolone acetate, prednisolone phosphate, prednisolone sodium, prednisone,triamcinolone acetonide, triamcinolone hexacetonide (except(a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 2/40

concentration that provides 1% or less hydrocortisone in preparations for topical use on theskin,(b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other non-prescription medicinal ingredient that provides 1% or less hydrocortisone in preparations fortopical use on the skin,(c) clobetasone butyrate, when sold in a concentration of 0.05% in cream preparations fortopical use on the skin,(d) fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray thatdelivers 50 mcg per metered spray for individuals 18 years of age and older),(e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50mcg per spray for those 12 years of age and older, and(f) triamcinolone acetonide in a nasal spray that delivers 55 mcg per spray for adults andchildren 12 years of age and older

1 Agalsidase alfa1 Alatrofloxacin and its salts and derivatives1 Aldesleukin1 Alefacept1 Alemtuzumab1 Alendronic acid and its salts1 Alfacalcidol

1A Alfentanil1 Alfuzosin and its salts1 Aliskiren and its salts1 Alkyl nitrites1 Allergy serums2 Allethrins (pyrethrins)1 Allopurinol1 Allylisopropylacetylurea1 Almotriptan and its salts3 Aloe vera latex, its extracts and derivatives (except aloin) (dosage forms for systemic use

containing more than 300 mg per dosage unit)1 Alpha-chloralose1 Alphadolone and its salts1 Alphaxalone1 Alprazolam1 Alteplase and its salts and derivatives1 Altrenogest1 Altretamine3 Aluminum oxide1 Alverine and its salts (for parenteral use)1 Amantadine and its salts1 Ambenonium chloride1 Ambrisentan1 Amifostine and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 3/40

1 Amikacin and its salts and derivatives1 Amiloride and its salts1 4-Amino-pteroyl aspartic acid and its salts1 Amino acid solutions (for parenteral use)1 Aminocaproic acid1 Aminoglutethimide1 Aminolevulinic acid and its salts and derivatives1 Aminophylline1 Aminopromazine [proquamezine] and its salts1 Aminopterin and its salts1 Aminopyrine and its derivativesV

1 4-Aminosalicylic acid and its salts1 5-Aminosalicylic acid1 Amiodarone and its salts1 Amitraz1 Amitriptyline and its salts1 Amlexanox and its salts and derivatives1 Amlodipine and its salts1 Ammonium bromide1 Amobarbital1 Amoxapine1 Amoxicillin and its salts and derivatives1 Amphetamine1 Amphotericin B and its salts and derivatives1 Ampicillin and its salts and derivatives1 Amprenavir and its salts and derivatives1 Amprolium and its saltsV

1 Amrinone and its salts1 Amsacrine and its salts2 Amylocaine and its salts (for ophthalmic or parenteral use)3 Amylocaine and its salts (preparations for topical use on mucous membranes except lozenges)1 Anagrelide and its salts1 Anakinra and its salts and derivatives1 Anastrozole1 Ancestim3 Anetholtrithione1 Anidulafungin

1A Anileridine2 Anisotropine and its salts3 Antazoline and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 4/40

2 Anthralin2 Antihemophilic factor, human1 Antipyrine (except preparations for topical use)V

2 Antipyrine (except otic preparations)3 Antipyrine (for otic use)1 Anti-thymocyte globulin1 Apomorphine and its salts1 Apraclonidine and its salts1 Apramycin and its saltsV

1 Aprepitant and its derivatives1 Aprotinin1 Argatroban and its salts and derivatives2 Arginine and its salts2 Artemisia, its preparations, extracts and compounds (except in trace amounts in homeopathic

preparations)1 L-Asparaginase1 Astemizole and its salts1 Atazanavir and its salts1 Atenolol and its salts1 Atipamezole and its salts1 Atomoxetine and its salts1 Atorvastatin and its salts1 Atovaquone1 Atracurium besilate1 Atropine and its salts (in ophthalmic or parenteral preparations)1 Auranofin1 Aurothioglucose1 Azacyclonol and its salts1 Azaribine1 Azathioprine and its salts1 Azatadine and its salts1 Azelaic acid1 Azithromycin and its salts and derivativesV

1 Azlocillin and its salts and derivatives1 Aztreonam and its salts1 Bacitracin and its salts and derivatives (for parenteral use)3 Bacitracin and its salts and derivatives (for ophthalmic use)1 Baclofen and its salts1 Bambuterol and its salts1 Basiliximab

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 5/40

1 Becaplermin2 Belladonna alkaloids, and their salts and derivatives (except in preparations for topical use or

in trace amounts in homeopathic preparations)3 Belladonna alkaloids, their salts and derivatives for topical use1 Bemegride1 Benactyzine and its salts1 Benazepril and its salts and derivatives1 Bendazac and its salts1 Benoxaprofen and its salts2 Benoxinate hydrochloride (oxybuprocaine) (for ophthalmic or parenteral use)1 Benserazide and its salts2 Bentiromide2 Benzalkonium and its salts (liquid preparations in concentrations of more than 2%)1 Benzathine penicillin and its salts and derivatives2 Benzethonium chloride (liquid preparations in concentrations of more than 1%)3 Benzocaine and its salts (for topical use on mucous membranes for teething)2 Benzocaine and its salts (for parenteral or ophthalmic use)3 Benzonatate1 Benzoyl peroxide (in concentrations greater than 5% or when sold in combination with another

medicinal ingredient)1 Benzphetamine1 Benztropine and its salts1 Benzydamine and its salts2 Benzyl benzoate1 Beractant3 Berberis vulgaris (Barberry)1 Betahistine and its salts1 Betaine and its salts when sold or recommended for the treatment of homocystinuria1 Betaxolol and its salts1 Bethanechol chloride1 Bethanidine and its salts1 Bevacizumab1 Bezafibrate and its salts and derivatives1 Bicalutamide1 Bimatoprost and its derivatives1 Biperiden and its salts3 Bisacodyl and its salts except when sold in

(a) concentrations of 5 mg or less per oral dosage unit or 10 mg or less per rectal dosageunit/suppository, and(b) package sizes containing no more than 50 mg of bisacodyl

1 Bishydroxycoumarin and its salts and derivatives1 Bisoprolol and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 6/40

1 Bitolterol and its salts1 Bivalirudin1 Bleomycin2 Boric acid and its salts (in preparations for systemic use, or ophthalmic preparations in

concentrations of greater than 2%) [Note: does not apply to contact lens solutions intended tobe rinsed off prior to placement of lens on the eye]

1 Bortezomib1 Bosentan and its salts and derivatives1 Botulinum Toxin Type A1 Botulinum Toxin Type B1 Bretylium tosylate1 Brimonidine and its salts1 Bromal1 Bromal hydrate1 Bromazepam and its salts1 Brometone1 Bromisoval1 Bromocriptine and its salts1 Bromoform3 Brompheniramine and its salts as a single entity for the treatment of allergies2 Buclizine2 Bufexamac1 Bumetanide and its salts and derivatives2 Bupivacaine and its salts (for parenteral or ophthalmic use)3 Bupivacaine and its salts (for topical use on mucous membranes except lozenges)

1A Buprenorphine1 Bupropion and its salts1 Buserelin and its salts1 Buspirone and its salts1 Busulfan2 Butacaine and its salts (for ophthalmic or parenteral use)

1A Butalbital1 Butaperazine and its salts1 Butoconazole and its salts

1A Butorphanol1 Butyl chloral hydrate1 Cabergoline and its salts1 Calcipotriol1 Calcitonin1 Calcitriol1 Calcium bromide

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 7/40

1 Calcium bromolactobionate1 Calcium carbimide1 Calcium chloride in injectable form for parenteral use2 Calcium disodium edetate1 Calcium gluconate in injectable form for parenteral nutrition3 Calcium polycarbophil1 Calcium salts when sold for the treatment of hyperphosphatemiaV

2 Camphor (in oleaginous vehicles and in liquid forms in concentrations greater than 11%)1 Candesartan and its salts and derivatives1 Candicidin and its salts and derivatives2 Cantharides, their preparations and derivatives1 Capecitabine and its salts and derivatives1 Capreomycin and its salts and derivatives1 Captodiamine and its salts1 Captopril and its salts1 Carbachol1 Carbamazepine1 Carbenicillin and its salts and derivatives1 Carbenoxolone and its salts1 Carbetocin and its salts1 Carbidopa and its salts1 Carbimazole3 Carbinoxamine and its salts1 Carbocisteine1 Carbomycin and its salts and derivatives1 Carboplatin1 Carbromal1 Carisoprodol1 Carmustine1 Carphenazine and its salts1 Carprofen and its salts and derivatives1 Carvedilol and its salts3 Casanthranol1 Caspofungin and its salts and derivatives1 Cefdinir and its salts and derivatives1 Cefepine and its salts and derivatives1 Cefonicide and its salts1 Cefoperazone and its salts and derivatives1 Cefprozil and its salts and derivatives1 Ceftibuten and its salts and derivatives

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 8/40

1 Celecoxib and its salts1 Cephalosporin C and its salts and derivatives3 Cerapon1 Cerivastatin and its salts1 Cetirizine and its salts (when sold in concentrations greater than 8.5 mg cetirizine base per

dosage unit)3 Cetirizine and its salts (in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine

base per dosage unit) in products marketed for pediatric use (under 12 years of age)1 Cetrorelix and its salts1 Cetuximab2 Charcoal (activated) when sold as a poisoning antidote3 Chlophedianol and its salts1 Chloral1 Chloral hydrate (oral)1 Chloralformamide1 Chloralimide1 Chlorambucil and its salts and derivatives1 Chloramphenicol and its salts and derivatives1 Chlorcyclizine and its salts (except in preparations for external use only)1 Chlordiazepoxide and its salts1 Chlorhexidine and its salts (when used as a topical oral preparation)V

1 Chlorisondamine and its salts1 Chlormezanone2 Chloroprocaine and its salts (for parenteral or ophthalmic use)3 Chloroprocaine and its salts (topical on mucous membranes except lozenges)1 Chloroquine and its salts1 Chlorothiazide and its salts and derivativesV

1 Chlorpromazine and its saltsV

1 Chlorpropamide1 Chlorprothixene and its salts3 Chlorzoxazone and its salts2 Cholecystokinin1 Cholestyramine resinV

2 Choline bitartrate (parenteral)1 Choline salicylate (when sold in combination with magnesium salicylate)1 Choline theophyllinate1 Choriogonadotropin alfa1 Chromium chloride (chromic chloride) in injectable form for parenteral nutrition2 Chymopapain (parenteral)2 Chymotrypsin (parenteral and ophthalmic)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 9/40

1 Ciclopirox and its salts1 Cilastatin and its salts1 Cilazapril and its salts and derivatives1 Cimetidine or its salts (except when sold in concentrations of 200 mg or less per oral dosage

unit and indicated for the treatment of heartburn)3 Cimetidine or its salts, when sold in concentrations of 100 mg or less per oral dosage unit and

indicated for the treatment of heartburn1 Cinacalcet and its salts2 Cinchocaine (dibucaine) and its salts (for ophthalmic or parenteral use)1 Cinchophene and its salts1 Cinoxacin1 Ciprofloxacin and its salts1 Cisapride and its salts1 Cisatracurium besilate1 Cisplatin1 Citalopram and its salts1 Cladribine and its salts1 Clarithromycin and its salts and derivativesV

3 Clemastine and its salts1 Clenbuterol and its salts2 Clidinium and its salts1 Clindamycin and its salts and derivatives1 Clobazam and its salts2 Clobetasone butyrate (when sold in a concentration of 0.05% clobetasone butyrate in cream

preparations for topical use on the skin)1 Clodronic acid and its salts1 Clofibrate1 Clomiphene and its salts1 Clomipramine and its salts1 Clonazepam and its salts1 Clonidine and its salts1 Clopidogrel and its salts1 Cloprostenol and its salts and derivatives1 Clorazepic acid and its salts1 Clotrimazole and its salts (except preparations for topical or intra-vaginal use)3 Clotrimazole and its salts (preparations for intra-vaginal use)1 Cloxacillin and its salts and derivatives1 Clozapine and its salts2 Coal tar (in concentrations of more than 10%)2 Codeine and its salts (in preparations exempted from the Regulations to the Controlled Drugs

and Substances Act (Canada))

JE022020

10

22

-Dru

g_Sc

he

du

les_

Re

gula

tio

n_C

han

ge_J

an2

02

0 v

20

20

.1 (

Po

sted

20

20

-01

-06

)

DR

UG

SC

HE

DU

LE

S R

EG

UL

AT

ION

CH

AN

GE

S –

JA

N 2

02

0

Th

e f

ollo

win

g a

me

ndm

en

ts t

o th

e S

ch

ed

ule

s t

o th

e D

rug

Sch

ed

ule

s R

eg

ula

tion

ma

de u

nd

er

the P

harm

acy O

pera

tio

ns a

nd

Dru

g

Sch

ed

ulin

g A

ct

cam

e into

forc

e, o

r w

ill c

om

e in

to fo

rce,

on t

he d

ate

in

dic

ate

d b

elo

w.

Th

e a

me

ndm

ents

ma

y n

ot ye

t b

e r

eflecte

d o

n

the D

rug

Sch

ed

ule

s R

eg

ula

tion

pu

blis

hed

by t

he B

ritish

Colu

mb

ia g

ove

rnm

ent o

n th

e B

C L

aw

s w

eb

site

(w

ww

.bcla

ws.c

om

).

OL

D E

NT

RY

N

EW

EN

TR

Y

IN F

OR

CE

DA

TE

1

Co

de

ine,

exce

pt

(a)

wh

en

pre

scrib

ed

as a

sin

gle

entity

,(b

)w

hen

inclu

de

d in

a p

repa

ratio

n c

onta

inin

g6

0 m

g o

r m

ore

per

dosag

e u

nit, o

r(c

)in

pre

para

tion

s e

xe

mp

ted

fro

m th

eR

eg

ula

tion

s to

th

e C

ontr

olle

d D

rugs a

nd

Su

bsta

nce

s A

ct (C

ana

da)

1

Co

de

ine a

nd

its

sa

lts,

exce

pt

(a)

wh

en

pre

scrib

ed

as a

sin

gle

entity

,(b

)w

hen

inclu

de

d in

a p

repa

ratio

n c

onta

inin

g6

0 m

g o

r m

ore

per

dosag

e u

nit,

(c)

wh

en

inclu

de

d in

a liq

uid

pre

pa

ratio

nco

nta

inin

g 1

.6 m

g o

r m

ore

pe

r m

L,

or

(d)

in p

rep

ara

tion

s e

xe

mp

ted fro

m th

eR

eg

ula

tion

s to

th

e C

ontr

olle

d D

rugs a

nd

Su

bsta

nce

s A

ct (C

anad

a)

Ja

nu

ary

2,

202

0

1A

1

A C

ode

ine w

hen

pre

scrib

ed

as a

sin

gle

entity

o

r w

hen

inclu

de

d in

a p

repa

ratio

n c

onta

inin

g 6

0

mg

or

mo

re p

er

dosag

e u

nit

1A

C

ode

ine a

nd

its

sa

lts w

he

n

(a)

pre

scrib

ed

as a

sin

gle

en

tity

,(b

)in

clu

de

d in

a p

repa

ratio

n c

onta

inin

g 6

0 m

go

r m

ore

per

dosag

e u

nit, o

r(c

)in

clu

de

d in

a liq

uid

pre

pa

ratio

n c

onta

inin

g1

.6 m

g o

r m

ore

per

mL

Ja

nu

ary

2,

202

0

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 10/40

1 Codeine, except(a) when prescribed as a single entity,(b) when included in a preparation containing 60 mg or more per dosage unit, or(c) in preparations exempted from the Regulations to the Controlled Drugs and SubstancesAct(Canada)

1A Codeine when prescribed as a single entity or when included in a preparation containing 60 mgor more per dosage unit

2 Collagenase (as debriding agent)1 Colchicine1 Colestipol and its salts1 Colfosceril and its derivatives1 Colistin and its salt and derivatives1 Copper chloride (cupric chloride) in injectable form for parenteral nutrition1 Copper sulfate in injectable form for parenteral nutrition1 CorticotrophinV

1 CosyntropinV

1 Cromoglycic acid and its salts (except sodium cromoglycate in concentrations of 2% or less, insolutions for ophthalmic or intranasal use)

3 Cromoglycic acid and its salts in solutions of sodium cromoglycate in concentrations of 2% orless, for ophthalmic or intranasal use

2 Crotamiton2 Cyclandelate2 Cyclazocine and its salts1 CyclizineV

1 Cyclobenzaprine and its salts2 Cyclomethacaine and its salts (for ophthalmic or parenteral use)2 Cyclopentamine and its salts1 Cyclopentolate and its salts (in preparations for parenteral or ophthalmic use, except when

sold for use in diagnostic procedures to an optometrist registered in a province of Canada)2 Cyclopentolate and its salts (except for ophthalmic or parenteral use)1 Cyclophosphamide1 Cycloserine1 Cyclosporine2 Cyproheptadine and its salts1 Cyproterone and its derivatives1 Cytarabine and its salts1 Dabigatran and its salts and derivatives1 Dacarbazine1 Daclizumab1 Dactinomycin1 Dalfopristin and its salts1 Dalteparin and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 11/40

1 Danaparoid and its salts and derivatives1 Danazol1 Danofloxacin and its salts3 Danthron1 Dantrolene and its salts1 Dapiprazole and its salts1 Daptomycin1 Darifenacin and its salts1 Dasatanib1 Daunorubicin and its salts1 Debrisoquin and its salts1 Deferasirox1 Deferoxamine and its salts3 Dehydrocholic acid and its salts1 Delavirdine and its salts1 Deoxycholic acid and its salts, when used in an injectable form3 Deoxycholic acid and its salts (except when used in an injectable form)1 Deracoxib1 Deserpidine and its alkaloids and salts1 Desflurane1 Desipramine and its salts3 Desloratadine and its salts and preparations (in products marketed for paediatric use — under

12 years of age)1 Desmopressin and its salts2 Desoxyribonuclease [pancreatic dornase]1 Detomidine and its salts3 Dexbrompheniramine and its salts3 Dexchlorpheniramine and its salts1 Dexfenfluramine and its salts1 Dexraoxane and its salts1 Dextroamphetamine or its salts3 Dextromethorphan and its salts (except in oral dosage forms in package sizes containing no

more than 300 mg dextromethorphan base or 409.3 dextromethorphan hydrobromide)1 Dextrose injection in concentrated solutions for parenteral nutrition2 Dextrose (sclerosing agents)

1A Diacetylmorphine1 Diazepam and its salts1 Diazoxide and its salts1 Dichloroacetic Acid1 Diclofenac and its salts, including but not limited to diclofenac diethylamine, diclofenac sodium

and diclofenac potassium, except when sold as a single medicinal ingredient for topical use onthe skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 12/40

2 Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skinfor not more than 7 days,(a) in concentrations greater than 1.16% and less than or equal to 2.32%, and(b) in package sizes containing greater than 2.6 g of diclofenac diethylamine

3 Diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skinfor not more than 7 days,(a) in concentrations greater than 1.16% and less than or equal to 2.32%, and(b) in package sizes containing no more than 2.6 g of diclofenac diethylamine

1 Dicloxacillin and its salts and derivatives2 Dicyclomine and its salts (except topicals and lozenges)1 Didanosine and its salts and derivatives1 Diethylbromacetamide1 Diethylcarbamazine and its salts1 Diethylstilbestrol and its derivatives1 Difloxacin and its salts and derivatives1 Diflunisal and its salts1 Digitalis lanata and its glycosides (Grecian foxglove)1 Digitalis purpurea and its glycosides (Common foxglove)1 Digoxin immune Fab (ovine)2 Dihydroquinidine and its salts (except phenylbarbiturate)1 Dihydrostreptomycin and its salts and derivativesV

1 Dihydrotachysterol1 Diiodohydroxyquin (except in preparations for topical use on the skin)2 Diiodohydroxyquin (for topical use)1 Diltiazem and its salts2 Dimenhydrinate and its salts (for parenteral use)3 Dimenhydrinate and its salts (for oral or rectal use)1 Dimercaprol3 Dimethothiazine1 Dimethyl sulfoxide, for veterinary use or when sold for the treatment of interstitial cystitis or

scleroderma in humans3 Dimeticone 100 cSt solution 50% w/w for topical use in the treatment of head lice1 2,4-Dinitrophenol and its salts and derivatives1 Dinoprostone and its salts and derivatives2 Diperodon and its salts (except for topical use)2 Diphenhydramine and its salts and preparations (for parenteral use or for topical use in

concentrations of greater than 2%)3 Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in

concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydraminehydrochloride)

1 Diphenidol and its salts1 Diphenoxylate or its salts1 Diphenylhydantoin (phenytoin) and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 13/40

3 Diphenylpyraline1 Dipivefrin and its salts1 Diprophylline and its salts1 Dipyridamole1 DirithromycinV

1 Disopyramide and its salts1 Disulfiram2 Dithranol (Anthralin)1 Dobutamine and its salts1 Docetaxel and its derivatives1 Dolasetron and its salts1 Domperidone1 Donepezil and its salts1 Dopamine and its salts, when sold for administration by injection1 Dornase alfa1 Dorzolamide and its salts1 Doxacurium chloride1 Doxapram1 Doxazosin and its salts1 Doxepin and its salts1 Doxercalciferol and its derivitaves1 Doxorubicin and its salts1 Doxycycline and its salts and derivatives (when sold for intramuscular administration in caged

birds)1 Doxylamine and its salts (when sold or recommended for use in the nausea or vomiting of

pregnancy)3 Doxylamine and its salts (except those sold for nausea and vomiting of pregnancy)1 Droperidol and its salts1 Drotrecogin1 Duloxetine and its salts1 Dutasteride2 Dyclonine (except for topical use on mucous membranes)3 Dyclonine and its salts (for topical use on mucous membranes, except lozenges)1 Econazole and its salts1 Ecothiophate and its saltsV

1 Ectylurea and its salts1 Eculizumab1 Edrophonium chloride1 Efalizumab1 Efavirenz1 Eflornithine and its salts and derivatives

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 14/40

3 Electrolyte solutions (for oral rehydration)1 Eletriptan and its salts1 Embutramide1 Emedastine and its salts1 Emtricitabine1 Emylcamate1 Enalaprilat and its salts and derivatives1 Enflurane1 Enfuvirtide1 Enoxaparin and its salts1 Enrofloxacin1 Entacapone1 Entecavir1 Ephedrine and its salts (in preparations containing more than 8 mg per unit dose or with a

label recommending more than 8 mg per dose or 32 mg per day, or labelled or implied for useexceeding 7 days, or if indicated for other than nasal congestion)

3 Ephedrine and its salts in combination products (in preparations containing no more than 8 mgper unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for usefor no more than 7 days, and indicated for nasal congestion)

2 Ephedrine and its salts in single entity products (in preparations containing no more than 8 mgper unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for usefor no more than 7 days, and indicated for nasal congestion)

1 Epinephrine and its salts (other than in pre-filled syringes intended for emergencyadministration by injection in the event of anaphylactic reactions to allergens)

2 Epinephrine and its salts (in pre-filled syringes intended for emergency administration byinjection in the event of anaphylactic reactions to allergens)

1 Epirubicine and its salts1 Epoprostenol and its salts1 Eprosartan and its salts and derivatives1 Epsiprantel1 Eptifibatide and its salts1 Ergot alkaloids and their saltsV

1 Erlotinib and its salts1 Ertapenem and its salts1 Erythrityl tetranitrate1 Erythromycin and its salts and derivativesV

1 Erythropoietin1 Escitalopram and its salts2 Esdepallethrin/piperonyl butoxide1 Esmolol and its salts1 Esomeprazole or its salts for human use including but not limited to esomeprazole magnesium

except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, inpackage sizes of no more than 280 mg of esomeprazole

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 15/40

3 Esomeprazole or its salts for human use when sold for the 14-day treatment for frequentheartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole

1 Esomeprazole or its salts for veterinary use1 Estazolam and its salts1 Estramustine and its salts1 Etanercept1 Ethacrynic acid1 Ethambutol and its salts2 Ethanolamine oleate

1A Ethchlorvynol1 Ethinamate4 Ethinyl estradiol (when used for emergency contraception)1 Ethionamide and its salts2 Ethoheptazine and its salts1 Ethomoxane and its salts1 Ethopropazine hydrochloride (profenamine and its salts)1 Ethotoin and its salts2 Ethyl Chloride (except in trace amounts)1 Ethyl trichloramate1 Ethylpapaverine and its salts1 Etidronic acid and its salts1 Etodolac and its salts and derivatives1 Etoposide and its derivatives1 Etravirine and its salts1 Etretinate1 Etymemazine and its salts1 Exemestane1 Ezetimibe1 Famciclovir and its salts1 Famotidine and its salts (except when sold in concentrations of 20 mg or less per oral dosage

unit and indicated for the treatment of heartburn)3 Famotidine and its salts (when sold in concentrations of 20 mg or less per oral dosage unit and

indicated for the treatment of heartburn, in package sizes containing more than 600 mg offamotidine)

1 Felodipine and its salts1 Fenfluramine and its salts1 Fenofibrate1 Fenoprofen and its salts1 Fenoterol and its salts

1A Fentanyl3 Fexofenadine hydrochloride (in products marketed for pediatric use — under 12 years of age)2 Fibrin

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 16/40

2 Fibrinolysin1 Filgrastim1 Finasteride1 Flavoxate and its salts1 Flecainide and its salts1 Fleroxacin and its salts and derivatives1 Floctafenine1 Florfenicol and its derivatives1 Fluconazole (except when sold in a concentration of 150 mg per oral dosage unit as a single

dose treatment and indicated for the treatment of vaginal candidiasis)3 Fluconazole (when sold in a concentration of 150 mg per oral dosage unit and indicated for the

treatment of vaginal candidiasis, in package sizes containing no more than 150 mg offluconazole)

1 Flucytosine1 Fludarabine and its salts and derivatives1 Flumazenil1 Flunarizine and its salts1 Flunixin and its salts and derivatives1 Fluoride and its salts (in solid oral dosage forms containing more than 1 mg of fluoride ion)3 Fluoride and its salts (oral preparations containing 1 mg or less of fluoride ion per dosage unit)1 Fluorouracil and its derivatives1 Fluoxetine and its salts1 Flupentixol and its salts and derivatives1 Fluphenazine and its salts1 Fluprostenol and its salts and derivatives1 Flurazepam and its salts1 Flurbiprofen and its salts1 Fluspirilene1 Flutamide2 Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray that

delivers 50 mcg per metered spray, for individuals 18 years of age and older and in packagesizes containing more than 120 metered sprays

3 Fluticasone propionate when sold for the treatment of allergic rhinitis in a nasal spray thatdelivers 50 mcg per metered spray, for individuals 18 years of age and older and in packagesizes containing no more than 120 metered sprays

1 Fluvastatin and its salts and derivatives1 Fluvoxamine and its salt1 Folic acidV

1 Folic acid (in preparations containing more than 1.0 mg of folic acid per dosage form or, wherethe largest recommended daily dosage shown on the label would, if consumed by a person,result in the daily intake by that person of more than 1.0 mg of folic acid)

1 Follicle stimulating hormone

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 17/40

1 Fomepizole and its salts1 Fondaparinux sodium1 Formestane and its salts and derivatives1 Formoterol and its salts1 Foscarnet sodium1 Fosfomycin and its salts1 Fosinopril and its salts1 Fosphenytoin and its salts3 Fractar1 Framycetin and its salts and derivativesV

1 Frovatriptan and its salts1 Fulvestrant1 Furaltadone and its saltsV

1 Furazolidone and its saltsV

1 FurosemideV

1 Fusidic acid and its salts1 Gabapentin and its salts and derivatives1 Galantamine and its salts and derivatives1 Gallamine triethiodide1 Gallium and its salts1 Ganciclovir and its salts1 Ganirelix and its salts and derivatives1 Gatifloxacin and its salts and derivatives1 Gefitinib1 Gemcitabine and its salts1 Gemfibrozil and its salts1 Gemifloxacin and its salts1 Gentamicin and its salts and derivatives2 Gentian Violet1 Glatiramer and its salts1 Gliclazide1 Glimepiride1 Glipizide2 Glucagon1 Glyburide and its salts and derivatives3 Glyceroargentinate2 Glycopyrrolate or its salts (except glycopyrronium bromide, including but not limited to

glycopyrrolate, when used orally or for inhalation)1 Glycopyrronium bromide (including but not limited to glycopyrrolate, when used orally or for

inhalation)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 18/40

1 Gold and its salts and derivatives, when sold for administration by injection1 Golimumab1 Gonadorelin and its salts1 Gonadotropin, chorionic (human)1 Gonadotropin, serum (human)1 Goserelin and its salts3 Gramicidin and its salts and derivatives (for ophthalmic use)1 Granisetron and its salts1 Grepafloxacin and its salts and derivatives1 Griseofulvin and its salts and derivativesV

1 Guanethidine and its salts1 Halazepam and its salt1 Halofantrine and its salts1 HaloperidolV

3 Haloprogin1 Halothane2 Heparin and its salts (except for topical use)3 Heparin and its salts (for topical use)1 Hetacillin and its salts and derivatives1 Hetastarch and its derivatives1 Hexachlorophene and its salts1 Hexacyclonate sodium1 Hexamethonium and its salts2 Histamine and its salts (except for topical use)1 Histrelin and its salts1 Homatropine and its salts (for ophthalmic or parenteral use or in preparations for oral use

containing more than 2 mg per dosage unit)2 Homatropine and its salts (for oral use in concentrations of 2 mg or less per dosage unit)2 Human insulin1 Hyaluronic acid and its salts (when sold or recommended for administration by intra-articular

injection to horses)2 Hyaluronic acid and its salts (preparations in concentrations of 5% or more)2 Hyaluronidase1 Hydralazine and its salts

1A Hydrocodone (dihydrocodeinone)1 Hydrocortisone or hydrocortisone acetateV (except when sold in a concentration that provides

1% or less hydrocortisone in preparations for topical use on the skin, for adults and children 2years of age and over, and in package sizes containing no more than 30 g)

3 Hydrocortisone or hydrocortisone acetate (when sold in a concentration that provides 1% orless hydrocortisone in preparations for topical use on the skin, for adults and children 2 yearsof age and over, and in package sizes containing no more than 30 g)

1A Hydromorphone (dihydromorphone)JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 19/40

2 Hydroquinone (topical preparations)1 Hydroxychloroquine and its salts1 4-Hydroxycoumarin and its derivatives (when sold or recommended as anticoagulants)2 Hydroxyephedrine and its salts1 Hydroxyurea1 Hydroxyzine and its salts and derivatives2 Hyoscine and its salts and derivatives [scopolamine] (except hyoscine butylbromide, when

recommended for parenteral use)1 Hyoscine butylbromide (when recommended for parenteral use)2 Hyoscyamine and its salts and derivatives (except for topical use)1 Ibandronic acid and its salts1 Ibuprofen and its salts except when sold in

(a) an oral dosage form that provides 400 mg or less per dosage unit, or(b) a modified-release oral dosage form that provides 600 mg or less per dosage unit

3 Ibuprofen and its salts containing 400 mg or less per oral dosage unit (when sold in packagesizes exceeding 18 000 mg)

3 Ibuprofen and its salts when sold in a modified-release oral dosage form that provides 600 mgor less per dosage unit

1 Ibutilide and its salts and derivatives1 Idarubicin and its salts1 Idoxuridine1 Ifosfamide1 Imatinib and its salts1 Imiglucerase1 Imipenem and its salts and derivatives1 Imipramine and its salts1 Imiquimod and its salts1 Indapamide and its salts1 Indinavir and its salts1 Indomethacin1 Infliximab1 Inhaled human insulin1 Inosiplex2 Insulin1 Interferon2 Iodinated glycerol2 Iodine and its salts and derivatives (except topical preparations or in oral doses of 1 mg or less

per day)3 Iodine and its salts and derivatives (for topical use)2 Iodochlorhydroxyquin (for topical use)1 Iodochlorhydroxyquin (except in preparations for topical use on the skin)2 Ipecac and its extracts and derivatives (when used as an emetic)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 20/40

1 Ipratropium and its salts1 Iproniazid and its salts1 Irbesartan and its salts1 Irinotecan and its salts2 Iron and its salts and derivatives (preparations with more than 30 mg elemental iron per solid

dosage unit or 5 mL oral liquid)1 Iron derivatives (for parenteral use)V

1 Isocarboxazid and its salts1 Isoflurane1 Isoniazid1 Isopropamide and its salts3 Isopropyl myristate in concentration of 50% (for use in the treatment of head lice)1 Isoproterenol (Isoprenaline) and its salts1 Isosorbide and its salts and derivatives1 Isotretinoin and its salts1 Isoxsuprine and its salts1 Isradipine and its salts1 Itraconazole and its salts1 Ivermectin and its derivatives (for human use or for veterinary use when sold for

intramuscular injection into horses or for administration to dogs and cats)1 Kanamycin and its salts and derivativesV

1 Ketamine and its salts1 Ketanserin and its salts1 Ketazolam and its salts1 Ketoconazole and its salts (except in preparations for topical use as a shampoo)1 Ketoprofene and its salts1 Ketorolac and its salts1 Ketotifen and its salts1 Labetalol and its salts3 Lactic acid (preparations in concentrations of more than 10%)1 Lactic acid (when recommended for use by injection as a tissue sclerosing agent)3 Lactulose1 Lamivudine and its salts1 Lamotrigine and its salts1 Lanreotide and its salts1 Lansoprazole and its salts1 Lanthanum salts (when sold for the treatment of hyperphosphatemia)1 Lapatinib and its salts1 Laronidase1 Latanoprost1 Leflunomide and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 21/40

1 Lenalidomide1 Letrozole1 Leucovorin and its salts1 Leuprolide and its salts1 Levallorphane and its salts1 Levamisole and its saltsV

2 Levargorphane and its salts1 Levetiracetam1 Levobunolol and its salts1 Levocabastine and its salts and derivatives1 Levocarnitine and its salts and derivatives, when sold for the treatment of primary or

secondary levocarnitine deficiency1 Levodopa and its salts2 Levonordefrine2 Levonorgestrel (when sold in concentrations of 1.5 mg or less per oral dosage unit, except

when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no morethan 1.5 mg levonorgestrel, packaged and labelled for emergency contraception)

3 Levonorgestrel (when sold in concentrations of 1.5 mg or less per oral dosage unit to be takenas a single dose of 1.5 mg, packaged and labelled for emergency contraception, in packagesizes containing no more than 1.5 mg of levonorgestrel)

1A Levorphanol1 Lidocaine (when in a preparation containing an equal amount of tetracaine and recommended

for topical use on the skin, in concentrations of 7% or higher)2 Lidocaine and its salts (for ophthalmic or parenteral use, or topical use on mucous

membranes, except lozenges)3 Lidocaine and its salts (for otic use)3 Lidocaine and prilocaine, eutectic mixture1 Lincomycin and its salts and derivativesV

2 Lindane1 Linezolid and its salts1 Liothyronine and its saltsV

1 Lipid solutions in injectable form for parenteral nutrition1 Lisdexamfetamine dimesylate1 Lisinopril and its salts and derivatives1 Lithium and its salts2 Lobelia and its alkaloids and preparations (except internal preparations containing not more

than 2 mg lobeline sulphate, external preparations containing not more than the equivalent of400 mg of crude lobelia or preparations containing 130 mg or less of lobelia inflata)

1 Lodoxamide and its salts and derivatives1 Lomefloxacin and its salts1 Lomustine2 Loperamide and its salts (in products marketed for pediatric use — under 12 years of age)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 22/40

1 Lopinavir1 Loracarbef and its salts and derivatives3 Loratidine and its salts and preparations in products marketed for pediatric use (under 12

years of age)1 Lorazepam and its salts1 Losartan and its salts1 Losoxantrone and its salts1 Lovastatin1 Loxapine and its salts1 L-Tryptophan, when sold

(a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unitor per daily dose, as a single ingredient or in combination with other ingredients, or(b) for human or veterinary use as a single ingredient intended for any route of administrationother than oral

1 Lumiracoxib1 Lutropin alfa3 Magnesium citrate (cathartics)1 Magnesium glutamate hydrobromide3 Magnesium salicylate (except oral dosage forms which also contain choline salicylate)2 Magnesium sulfate (for parenteral use)1 Magnesium sulfate in injectable form for parenteral nutrition1 Manganese and its salts in injectable form for parenteral nutrition2 Mannitol and its salts1 Maprotiline and its salts1 Maraviroc1 Marbofloxacin and its salts and derivatives1 Mazindol and its salts1 MebendazoleV

1 Mecamylamine and its salts1 Mechlorethamine and its salts1 Mecillinam and its salts and derivatives1 Meclizine and its saltsV (when sold in concentrations of more than 25 mg per dosage unit)3 Meclizine and its salts (when sold in concentrations of 25 mg or less per dosage unit)1 Meclofenamic acid and its salts1 Medetomidine and its salts1 Mefenamic acid and its salts1 Mefloquine and its salts and derivatives1 Megestrol and its salts1 Melanoma therapeutic vaccine1 Melarsomine and its salts when sold for the treatment of heartworm in dogs1 Meloxicam and its salts and derivatives

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 23/40

1 Melphalan1 Memantine and its salts1 Menotropins (human)1 Mepacrine and its salts1 Mepazine and its salts

1A Meperidine (pethidine)1 Mephenoxalone1 Mephentermine and its salts2 Mepivacaine and its salts (for ophthalmic or parenteral use)3 Mepivacaine and its salts (for topical use on mucous membranes, except lozenges)1 Meprobamate1 Mercaptopurine1 Meropenem and its salts and derivatives1 Mesna1 Mesoridazine and its salts1 Metaldehyde1 Metaraminol bitartrate2 Metathoheptazine and its salts1 Metformin and its salts and derivatives1 Methacholine and its salts

1A Methadone1 Methamphetamine2 Methantheline and its salts

1A Methaqualone1 Methazolamide and its salts2 Methdilazine and its salts2 Methenamine and its salts (except for topical use)2 Metheptazine and its salts1 Methicillin and its salts and derivatives1 Methimazole1 Methisazone3 Methocarbamol (except for parenteral use)2 Methocarbamol (for parenteral use)1 Methoin (Mephenytoin) and its salts1 Methotrexate and its salts1 Methotrimeprazine and its salts1 Methoxamine and its salts1 Methoxsalene1 Methoxy polyethylene glycol-epoetin beta2 Methyl salicylate (in liquid dosage forms in concentrations greater than 30%)1 Methyldopa and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 24/40

2 Methylene Blue (for parenteral use)1 Methylparafynol1 Methylphenidate or its salts1 Methyprylon1 Methysergide and its salts and derivatives1 Metoclopramide1 Metolazone and its salts1 Metomidate and its salts1 Metopimazine and its salts1 Metoprolol and its salts1 Metronidazole1 Metyrapone and its salts1 Mexiletine and its salts1 Mezlocillin and its salts and derivatives1 Micafungin and its salts1 Miconazole and its salts (except in preparations for topical or vaginal use)3 Miconazole and its salts (for vaginal use)1 Midazolam and its salts1 Midodrine and its salts1 Mifepristone or its derivatives1 Miglustat1 Milbemycin and its derivatives1 Milrinone and its salts3 Mineral tar (except shampoos with concentrations of less than 5%)1 Minoxidil except when sold in preparations for topical use in concentrations of 5% or less1 Mirtazapine and its salts1 Mitomycin and its salts1 Mitotane (o,p'-DDD)1 Mitoxantrone and its salts1 Mivacurium chloride1 Modafinil and its salts1 Molgramostim2 Monobenzone2 Monoethanolamine oleate1 Montelukast and its salts

1A Morphine1 Moxidectin and its derivatives when sold for the prevention of heartworm in dogs1 Moxifloxacin and its salts and derivatives1 Mupirocin1 Muromonab-CD3

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 25/40

1 Mycophenolic acid and its salts and derivatives1 Nabumetone1 Nadolol and its salts1 Nadroparin and its salts1 Nafarelin and its salts and derivatives1 Nafcillin and its salts and derivatives1 Nalidixic acid1 Nalmefene and its salts1 Naloxone and its salts (except when used for opioid overdose emergencies)1 Naltrexone and its salts and derivatives2 Naphazoline and its salts (in nasal preparations for pediatric use)1 Naproxen and its salts (except when sold as naproxen sodium 220 mg per oral dosage unit)3 Naproxen sodium 220 mg per oral dosage unit (when sold in products labeled with a

recommended maximum daily dose of 440 mg, and in package sizes exceeding 6 600 mg)1 Naratriptan and its salts3 Narcotine and its salts (Noscapine)1 Nateglinide and its salts and derivatives1 Nedocromil and its salts1 Nefazodone and its salts1 Nelarabine1 Nelfinavir and its salts1 Neocinchophen and its salts1 Neomycin and its salts and derivativesV

1 Neostigmine salts1 Nepafenac1 Netilmicin and its salts and derivatives1 Nevirapine and its salts1 Nialamide and its salts1 NicarbazinV

1 Nicardipine and its salts1 Nicotine and its salts for human use, except

(a) in natural substances,(b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit,(c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day,(d) in a form to be administered into the oral cavity by means of a non-active device (one thatoperates on energy generated by the human body or by gravity) that delivers 4 mg or less ofnicotine per dose for buccal absorption, or(e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit

2 Nicotinic acid [niacin] in extended-release formulations, except when sold in a modified-release oral dosage form that provides 500 mg or more per dosage unit or per daily dose

1 Nicotinic acid when sold in (a) a modified-release oral dosage form that provides 500 mg ormore per dosage unit or per daily dose, or (b) an immediate-release oral dosage form thatprovides more than 500 mg per dosage unit or per daily dose

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 26/40

1 Nicotinyl-tartrate1 Nifedipine1 Nikethamide1 Nilotinib and its salts1 Nilutamide1 Nimodipine and its salts1 Nitrazepam and its salts1 Nitric oxide1 Nitrofurantoin and its saltsV

2 Nitroglycerin (immediate-release sublingual dosage forms)1 Nitroglycerin (except for immediate-release sublingual dosage forms)1 Nitroscanate1 Nizatadine and its salts1 Nomifensine and its salts2 Norepinephrine and its salts (levarterenol, noradrenaline)1 Norfloxacin4 Norgestrel (when used for emergency contraception)

1A Normethadone1 Nortriptyline and its salts3 Noscapine1 Novobiocin and its salts and derivativesV

1 Nylidrin and its salts1 Nystatin and its salts and derivativesV (except preparations for topical use on the skin)3 Nystatin and its salts and derivatives (in topical preparations for use on the skin)1 Octatropine methylbromide1 Octreotide1 Ofloxacin and its salts1 Olanzapine and its salts1 Oleandomycin and its salts and derivativesV

1 Olmesartan and its salts and derivatives1 Olopatadine and its salts1 Olsalazine and its salts1 Omalizumab1 Omeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a

daily dose of 20mg in package sizes of no more than 280 mg of omeprazole2 Omeprazole or its salts when sold for the 14-day treatment for frequent heartburn at a daily

dose of 20 mg in package sizes of no more than 280 mg of omeprazole1 Ondansetron and its salts1 Orbifloxacin and its salts and derivatives1 Orciprenaline (Metaproterenol) and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 27/40

1 Orlistat1 Ormetoprim and its salts1 Ornidazole3 Orphenadrine citrate1 Orphenadrine hydrochloride1 Oseltamivir and its salts1 Oxacillin, and its salts and derivatives1 Oxaliplatin1 Oxanamide1 Oxaprozin and its salts and derivatives1 Oxazepam and its salts1 Oxcarbazepine3 Oxethazine1 Oxolinic acid and its salts1 Oxprenolol and its salts2 Oxybuprocaine and its salts (benoxinate) (for ophthalmic or parenteral use)3 Oxybuprocaine and its salts (for topical use on mucous membranes, except lozenges)1 Oxybutynin and its salts

1A Oxycodone2 Oxymetazoline and its salts (in nasal preparations for pediatric use)1 Oxyphenbutazone and its salts2 Oxyquinoline1 Oxytocin1 Paclitaxel and its derivatives1 Palifermin1 Paliperidone and its salts and derivatives1 Palivizumab1 Pamidronic acid and its salts1 Pancreatic enzymes (in products for the treatment of established pancreatic insufficiency)1 Pancreatic extracts when sold in a dosage form that provides more than 20 000 USP units of

lipase activity per dosage unit or indicated for the treatment of pancreatic exocrineinsufficiency

1 Pancreatin (in products for the treatment of established pancreatic insufficiency)1 Pancreatin when sold in a dosage form that provides more than 20 000 USP units of lipase

activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency1 Pancrelipase (in products for the treatment of established pancreatic insufficiency)1 Pancrelipase when sold in a dosage form that provides more than 20 000 USP units of lipase

activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency1 Pancuronium and its salts1 Panitumumab1 Pantoprazole and its salts1 Papaveretrine and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 28/40

1 Papaverine and its salts1 Paraldehyde1 Paramethadione1 Pargyline and its salts1 Paricalcitol1 Paromomycin1 Paroxetine and its salts2 Paroxypropione1 Pegaptanib and its salts1 Pegfilgrastim1 Pegvisomant1 Pemetrexed and its salts1 Penciclovir and its salts1 Penicillamine1 Pentaerythritol tetranitrate2 Pentagastrin and its salts1 Pentamidine and its salts

1A Pentazocine1 Pentolinium tartrate1 Pentosan polysulfate and its salts1 Pentostatin and its salts1 Pentoxifylline and its salts1 Perflutren1 Pergolide and its salts1 Pericyazine and its salts1 Perindopril and its salts2 Permethrin1 Perphenazine and its salts1 Phacetoperane and its salts1 Phenacemide1 Phenacetin1 Phenaglycodol1 Phenazopyridine and its salts1 Phendimetrazine and its salts1 Phenelzine and its salts1 Phenformin and its salts1 Pheniprazine and its salts1 Phenmetrazine and its salts1 Phenobarbital or its salts2 Phenol (preparations with concentration of more than 20%)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 29/40

2 Phenoxybenzamine and its salts1 Phenthoxate and its salts1 Phentolamine and its salts1 Phenylbutazone and its salts1 Phenylephrine and its salts (in preparations for parenteral or ophthalmic use in concentrations

greater than 2.5%)2 Phenylephrine and its salts and preparations (in nasal preparations for pediatric use, in

concentrations of 2.5% or less)1 Phenylindanedione and its derivatives1 Phenylpropanolamine and its salts and derivatives for veterinary use3 Phenyltoloxamine and its salts1 Physostigmine salicylate (except preparations for oral or topical use only)V

2 Physostigmine salicylate (for oral or topical use)1 Phytocannabinoids produced by, or found in, the cannabis plant and substances that are

duplicates of such phytocannabinoids, except(a) derivatives of cannabis as defined in subsection 2 (1) of the Cannabis Act (Canada) thatare exempt from the application of that Act under the Industrial Hemp Regulations (Canada)and that do not contain an isolated or concentrated phytocannabinoid or a synthetic duplicateof that phytocannabinoid,(b) anything referred to in Schedule 2 to the Cannabis Act (Canada) that contains no morethan 10 µg/g delta-9-tetrahydrocannabinol and that does not contain an isolated orconcentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid, or(c) anything referred to in the Cannabis Exemption (Food and Drugs Act) Regulations (Canada)that is exempt from the application of the Food and Drugs Act (Canada)

1 Pilocarpine and its salts1 Pimecrolimus1 Pimobendan1 Pimozide1 Pinaverium bromide1 Pindolol and its salts1 Pioglitazone and its salts1 Pipecuronium bromide1 Piperacetazine and its salts2 Piperazine and its salts1 Piperilate and its salts1 Pipobroman1 Pipotiazine and its salts1 Pipradol and its salts1 Pirbuterol and its salts1 Pirenzepine and its salts1 Pirlimycin and its salts1 Piroxicam and its salts1 Pizotyline and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 30/40

1 Podophyllum and the following extracts and active principles (when sold or recommended fortopical use): podophyllum toxin and podophyllum resin

2 Polyacrylamide3 Polymyxin B and its salts and derivatives (for ophthalmic use)1 Polymyxin B and its salts and derivatives, (except for topical use or for local action in the oral

cavity or nasal passages)V

1 Polysulfated glycosaminoglycan1 Ponazuril1 Poractant alfa1 Porfimer and its salts1 Posaconazole1 Potassium bromide1 Potassium citrate (when recommended for the treatment of renal tubular acidosis and kidney

stones)1 Potassium gluconate when sold or recommended for administration to cats1 Potassium para-aminobenzoate (except in preparations for topical use on the skin)2 Potassium salts (in oral preparations containing more than 5 mmol per single dose, except

(a) potassium bromide,(b) potassium gluconate when sold or recommended for administration to cats,(c) potassium para-aminobenzoate, and(d) potassium citrate when recommended for the treatment of renal tubular acidosis andkidney stones)

1 Potassium salts (in preparations for injection)2 Povidone - iodine (vaginal preparations, except in concentrations of 5% or less)3 Povidone - iodine (topical preparations, except in concentrations of 5% or less)1 Pralidoxime and its salts1 Pramipexole and its salts2 Pramoxine and its salts (for ophthalmic or parenteral use)3 Pramoxine and its salts (for topical use on mucous membranes, except lozenges)1 Pravastatin and its salts1 Prazepam and its salts1 Praziquantel, except when sold for the treatment of the tapeworm Anoplocephala perfoliata in

horses1 Prazosin and its salts1 Pregabalin and its salts and derivatives1 Prenylamine and its salts2 Prilocaine and its salts (for ophthalmic or parenteral use)3 Prilocaine and its salts (for topical use on mucous membranes, except lozenges)1 Primaquine and its salts1 PrimidoneV

1 Probenecid and its salts1 Probucol

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 31/40

1 Procainamide and its salts2 Procaine and its salts (for ophthalmic or parenteral use)3 Procaine and its salts (for topical use on mucous membranes, except lozenges)1 Procarbazine and its salts1 Procaterol and its salts1 Prochlorperazine and its salts1 Procyclidine and its salts1 Prodilidine and its salts1 Profenamine and its salts4 Progestin (when used for emergency contraception)1 Proguanil and its salts1 Promazine and its saltsV

2 Promethazine and its salts (except for topical use)3 Promethazine and its salts (for topical use)1 Propafenone and its salts2 Propantheline and its salts2 Proparacaine and its salts (for ophthalmic or parenteral use)3 Proparacaine and its salts (for topical use on mucous membranes, except lozenges)1 Propofol

1A Propoxyphene1 Propranolol and its salts2 Propylhexedrine1 Proquamezine [aminopromazine] and its salts (for internal use)1 Prostaglandins and their salts and derivatives2 Protamine and its salts1 Prothipendyl hydrochloride1 Protirelin1 Protriptyline and its salts3 Pseudoephedrine and its salts and preparations in combination products2 Pseudoephedrine and its salts and preparations in single entity products2 Pyrantel and its salts1 Pyrazinamide2 Pyrethrins (allethrins)2 Pyrethrins (allethrins) /piperonyl butoxide1 Pyridostigmine bromide1 Pyrimethamine and its salts2 Pyrvinium and its salts1 Quetiapine and its salts1 Quinagolide and its salts1 Quinapril and its salts and derivatives

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 32/40

1 Quinidine salts1 Quinine salts1 Quinupristin and its salts1 Rabeprazole and its salts2 Racemethionine1 Raloxifene and its salts1 Raltegravir and its salts1 Raltitrexed and its salts and derivatives1 Ramipril and its salts and derivatives1 Ranibizumab1 Ranitidine and its salts (except when sold in concentrations of 150 mg or less per oral dosage

unit and indicated for the treatment of heartburn)3 Ranitidine and its salts (when sold in concentrations of 150 mg or less per oral dosage unit and

indicated for the treatment of heartburn, in package sizes containing more than 4 500 mg ofranitidine)

1 Rasburicase1 Raubasine and its salts1 Rauwolfia1 Remoxipride and its salts1 Repaglinide and its salts and derivatives1 Rescinnamine and its salts1 Reserpine and its saltsV

1 Resocortol and its derivatives1 Retapamulin1 Reviparin and its salts1 Ribavirin1 Rifabutin and its salts1 Rifampin and its salts and derivatives1 Riluzole and its salts1 Risedronic acid and its salts1 Risperidone and its salts1 Ritodrine and its salts1 Ritonavir1 Rituximab1 Rivaroxaban1 Rivastigmine and its salts1 Rizatriptan and its salts1 Rocuronium bromide1 Rofecoxib1 Romifidine and its salts1 Romiplostim

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 33/40

1 Ronidazole and its salts and derivativesV

1 Ropinirole and its salts2 Rose Bengal1 Rosiglitazone and its salts1 Rosoxacin and its salts1 Rosuvastatin and its salts2 Rue and its preparations and extracts1 Salbutamol and its salts1 Salicylic acid (when sold in topical formulations containing salicylic acid at concentrations

greater than 20% or with a pH less than 3.0, or both, except when sold to be applied to warts,corns or calluses)

2 Salicylic acid (when sold to be applied to warts, corns or calluses in topical preparations inconcentrations greater than 40%)

1 Salmeterol and its salts1 Salsalate and its salts and derivatives1 Saquinavir and its salts and derivatives1 Saralasin and its salts1 Sargramostin2 Scopolamine and its salts (hyoscine)1 Secobarbital or its salts1 Selegiline and its salts2 Selenium (for parenteral use)1 Selenium in injectable form for parenteral nutrition1 Sermorelin and its salts1 Sertraline and its salts1 Sevelamer hydrochloride1 Sex hormonesV (the exemption from requiring a prescription if sold for veterinary use does not

apply to those listed separately elsewhere in this schedule and those listed in the drugschedules associated with the Controlled Drugs and Substances Act (Canada), except thosecontained in an agricultural implant)

1 Sibutramine and its salts1 Sildenafil and its salts2 Silver nitrate1 Simvastatin2 Sincalide1 Sirolimus and its derivatives1 Sitagliptin and its salts1 Sitaxentan and its salts2 Sodium acetate (for parenteral use)1 Sodium acetate in injectable form for parenteral nutrition1 Sodium aurothiomalate3 Sodium biphosphate (cathartic)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 34/40

2 Sodium biphosphate (for parenteral use)1 Sodium bromide1 Sodium chloride in injectable form for parenteral nutrition2 Sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations

of more than 0.9%) [NOTE: Does not apply to contact lens solutions intended to be rinsed offprior to insertion into eye]

2 Sodium citrate (for parenteral use)1 Sodium fluoride (in solid oral dosage forms containing more than one milligram of fluoride

ion)V

2 Sodium iodide (for sclerosing)1 Sodium iodine in injectable form for parenteral nutrition1 Sodium nitroprusside and its salts3 Sodium phosphate (cathartics)2 Sodium phosphate (for parenteral use)1 Sodium phosphate in injectable form for parenteral nutrition2 Sodium picosulphate for oral purgatives, 10 mg per pack (when found in preparations with

magnesium oxide 3.5 g and citric acid 12 g)1 Sodium polystyrene sulfonate2 Sodium tetradecyl sulfate1 Solifenacin and its salts1 Somatostatin1 Somatrem1 Somatropin1 Sotalol and its salts1 Spectinomycin and its salts and derivativesV

1 Spiramycin and its salts and derivativesV

1 Spironolactone1 Stavudine2 Stramonium and its preparations, extracts, and compounds2 Streptokinase (as a debriding agent)1 Streptokinase/streptodornase1 Streptomycin and its salts and derivativesV

1 Streptozocin2 Strontium and its salts (for parenteral use)1 Strontium bromide1 Succinimide and its salts and derivatives (except those compounds used for decontaminating

water)1 Succinylcholine and its salts1 Sucralfate

1A Sufentanil1 Sulconazole and its salts

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 35/40

1 Sulfinpyrazone and its salts1 Sulindac and its salts1 Sulphonamides and their salts and derivativesV

1 Sulphones and their derivatives1 Sumatriptan and its salts1 Sunitinib and its salts1 Suprofen and its salts2 Sutilains1 Suxamethonium chloride1 Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of

derivatives and isomers, as listed in the schedules associated with the Controlled Drugs andSubstances Act (Canada) and the Narcotic Control Regulations (Canada)

1 Tacrolimus and its derivatives1 Tadalafil and its salts1 Tamoxifen and its salts1 Tamsulosin and its salts

1A Tapentadol1 Tazarotene1 Tazobactam and its salts and derivatives1 Teflubenzuron1 Tegafur and its salts1 Tegaserod and its salts1 Telbivudine1 Telithromycin and its salts and derivatives1 Telmisartan and its salts and derivatives1 Temazepam and its salts1 Temozolomide and its salts1 Tenecteplase and its salts and derivatives1 Teniposide1 Tenofovir and its salts and derivatives1 Tenoxicam and its salts1 Terazosin and its salts1 Terbinafine and its salts1 Terbutaline and its salts1 Terconazole and its salts1 Terfenadine and its salts1 Teriparatide and its salts1 Terlipressin and its salts1 Tetrabenazine and its salts2 Tetracaine and its salts (for ophthalmic or parenteral use)3 Tetracaine and its salts (for topical use on mucous membranes, except lozenges)

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 36/40

1 Tetracaine (when in a preparation containing an equal amount of lidocaine and recommendedfor topical use on the skin, in concentrations of 7% or higher)

1 Tetracycline and its salts and derivativesV (the exemption from requiring a prescription if soldfor veterinary use does not apply if sold as doxycycline for intramuscular administration incaged birds)

2 Tetrahydrozoline (in nasal preparations for pediatric use)1 Thalidomide1 Theophylline and its salts1 ThiabendazoleV

1 Thiethylperazine and its salts1 Thiocarlide1 Thioguanine1 Thiopropazate and its salts1 Thioproperazine and its salts1 Thioridazine and its salts1 Thiotepa1 Thiothixene and its salts1 Thiouracil and its derivatives2 Thrombin2 Thyroglobulin1 ThyroidV

2 Thyrotropin1 Thyrotropin alfa1 Thyroxin and its salts1 Tiaprofenic acid and its salts1 Ticarcillin and its salts and derivatives1 Ticlopidine and its salts1 Tilmicosin1 Tiludronic acid and its salts1 Timolol and its salts1 Tinidazole1 Tinzaparin and its salts1 Tioconazole and its salts (except in preparations for topical or intra-vaginal use in humans)V

3 Tioconazole and its salts (in preparations for intra-vaginal use)1 Tiotropium bromide1 Tipranavir and its salts1 Tirofiban and its salts and derivatives1 Tizanidine and its salts1 Tobramycin and its salts and derivatives1 Tocainide and its salts1 Tolazamide

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 37/40

1 Tolazoline and its salts1 Tolbutamide1 Tolcapone1 Tolfenamic acid and its salts and derivatives1 Tolmetin and its salts1 Tolterodine and its salts1 Topiramate1 Topotecan and its salts1 Torasemide and its salts1 Toremifene and its salts1 Tramadol or its salts1 Trandolaprilat and its salts and derivatives1 Tranexamic acid1 Tranylcypromine1 Trastuzumab1 Trazodone and its salts1 Treosulfan1 Treprostinil and its salts1 Tretamine1 Tretinoin and its salts and derivatives2 Triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray for

adults and children 12 years of age and older, in package sizes containing more than 120metered sprays

3 Triamcinolone acetonide in an aqueous nasal spray that delivers 55 mcg per metered spray foradults and children 12 years of age and older, in package sizes containing no more than 120metered sprays

1 Triamterene and its salts1 Triazolam and its salts1 Tricaine and its salts3 Triethanolamine oleate3 Triethanolamine salicylate (in concentrations greater than 20%)1 Trifluoperazine and its salts1 Triflupromazine and its salts1 Trifluridine1 Trihexyphenidyl and its salts1 Triiodothyropropionic acid1 Trilostane1 Trimebutine and its salts1 Trimeprazine and its saltsV

1 Trimethadione1 Trimethaphan camsylate

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 38/40

1 Trimethoprim and its salts1 Trimetrexate and its salts1 Trimipramine and its salts1 Trioxsalen3 Tripelennamine and its salts3 Triprolidine1 Troglitazone1 Tropicamide and its salts (in preparations for parenteral or ophthalmic use, except when sold

for use in diagnostic procedures to an optometrist registered in a province of Canada)1 Trospium chloride1 Trovafloxacin and its salts and derivatives1 Tubocurarine and its salts1 Tybamate1 Tylosin and its salts and derivatives (when sold for the treatment of chronic colitis in dogs)1 Tylosin and its salts and derivativesV (except when sold for the treatment of chronic colitis in

dogs)3 Tyrothricine1 Ulipristal or its salts or derivatives (including but not limited to ulipristal acetate)1 Unoprostone and its salts and derivatives1 Uracil and its salts, when sold for the treatment of cancer2 Urea (in topical preparations in concentrations of more than 25%)1 Ursodeoxycholic acid and its salts1 Ustekinumab1 VaccinesV (except influenza, vaccines which are part of a routine immunization program, those

requiring special enhanced public access due to disease outbreaks and cholera vaccine (oral,inactivated) when used for prophylaxis against traveler's diarrhea due to enterotoxigenicescherichia coli (ETEC))

2 Vaccines (influenza, vaccines which are part of a routine immunization program, thoserequiring special enhanced public access due to disease outbreaks and cholera vaccine (oral,inactivated) when used for prophylaxis against traveler's diarrhea due to enterotoxigenicescherichia coli (ETEC))

1 Valaciclovir and its salts1 Valdecoxib and its salts1 Valganciclovir and its salts and derivatives1 Valproic acid and its salts1 Valrubicin and its derivitaves1 Valsartan and its salts and derivatives1 Vancomycin and its salts and derivatives1 Vardenafil and its salts1 Varenicline and its salts1 Vasopressin and its salts1 Vecuronium bromide

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 39/40

1 Vedaprofen and its salts and derivatives3 Vegetable tar (except shampoos in concentrations of 5% or less)1 Venlafoxine and its salts1 Verapamil and its salts1 Veratrum album and its alkaloids and their saltsV

1 Veratrum viride and its alkaloids and their saltsV

1 Verteporfin and its salts and derivatives1 Vidarabine1 Vigabatrin and its salts and derivatives1 Vinblastine and its salts1 Vincristine and its salts1 Vindesine and its salts1 Vinorelbine and its salts1 Viomycin and its salts and derivatives1 Virginiamycin and its salts and derivativesV

1 Vitamin AV

1 Vitamin A in oral dosage form containing more than 10 000 International Units of Vitamin Aper dosage form or, where the largest recommended daily dosage shown on the label would, ifconsumed by a person, result in the daily intake by that person of more than 10 000International Units of Vitamin A

1 Vitamin B12 with Intrinsic Factor Concentrate1 Vitamin DV

1 Vitamin D in oral dosage form containing more than 1 000 International Units of Vitamin D perdosage form or, where the largest recommended daily dosage shown on the label would, ifconsumed by a person, result in the daily intake by that person of more than 1 000International Units of Vitamin D

1 Vitamin K V (except Vitamin K1 and Vitamin K2 sold(a) for external use in humans, or(b) in an oral dosage form for use in humans if the maximum recommended daily dose is0.120 mg or less)

2 Vitamins (any parenterals not otherwise scheduled in Schedule I)1 Vitamins in injectable form for parenteral nutrition1 Voriconazole1 Vorinostat1 Xanthinol nicotinate1 Xylazine and its salts2 Xylometazoline and its salts (in nasal preparations for pediatric use)2 Xylose1 Yohimbine and its salts1 Zafirlukast and its salts1 Zalcitabine and its salts1 Zanamivir and its salts and derivatives

JE022020

1/6/2020 Drug Schedules Regulation

www.bclaws.ca/civix/document/id/complete/statreg/9_98 40/40

1 Zeranol1 Zidovudine1 Zinc chloride in injectable form for parenteral nutrition1 Zinc sulfate in injectable form for parenteral nutrition1 Ziprasidone and its salts1 Zoledronic acid and its salts and derivatives1 Zomepirac and its salts1 Zopiclone and its salts1 Zuclopenthixol and its salts and derivatives

V. Prescription not required if sold for veterinary use, provided that the product is labelled by themanufacturer "for agricultural use only" or "for veterinary use only"

[Provisions relevant to the enactment of this regulation: Pharmacy Operations and DrugScheduling Act, S.B.C. 2003, c. 77, s. 22]

Copyright (c) Queen's Printer, Victoria, British Columbia, Canada

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 1/9

1

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

Narcotic Control Regulations (C.R.C. (Consolidated Regulations of Canada), c. 1041)Regulations are current to 2019-12-03 and last amended on 2018-05-20.

SCHEDULE(Section 2)

Opium Poppy (Papaver somniferum), its preparations, derivatives, alkaloids and salts,including:

Opium

Codeine (methylmorphine)

Morphine (7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol)

Thebaine (paramorphine)

and the salts, derivatives and salts of derivatives of the substances set out insubitems (1) to (4), including:

Acetorphine (acetyletorphine)

Acetyldihydrocodeine (4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol acetate)

Benzylmorphine (7,8-didehydro-4,5-epoxy-17-methyl-3-(phenylmethoxy) morphinan-6-ol)

Codoxime (dihydrocodeinone O-(carboxymethyl)oxime)

Desomorphine (dihydrodeoxymorphine)

Diacetylmorphine (heroin)

Dihydrocodeine (4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol)

Dihydromorphine (4,5-epoxy-17-methylmorphinan-3,6-diol)

Ethylmorphine (7,8-didehydro-4,5-epoxy-3-ethoxy-17-methylmorphinan-6-ol)

Etorphine (tetrahydro-7α-(1-hydroxy-1-methylbutyl)-6,14-endo-ethenooripavine)

Hydrocodone (dihydrocodeinone)

Hydromorphinol (dihydro-14-hydroxymorphine)

Hydromorphone (dihydromorphinone)

Methyldesorphine (Δ6-deoxy-6-methylmorphine)

Methyldihydromorphine (dihydro-6-methylmorphine)

Metopon (dihydromethylmorphinone)

Morphine-N-oxide (morphine oxide)

Myrophine (benzylmorphine myristate)

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 2/9

(23)

(24)

(25)

(26)

(27)

(28)

(29)

(30)

(31)

(32)

(33)

(33.1)

(34)

(34.1)

(34.2)

(34.3)

(34.4)

(35)

(36)

(37)

2

(1)

(2)

(3)

Nalorphine (N-allylnormorphine)

Nicocodine (6-nicotinylcodeine)

Nicomorphine (dinicotinylmorphine)

Norcodeine (N-desmethylcodeine)

Normorphine (N-desmethylmorphine)

Oxycodone (dihydrohydroxycodeinone)

Oxymorphone (dihydrohydroxymorphinone)

Pholcodine (3-[2-(4-morpholinyl)ethyl]morphine)

Thebacon (acetyldihydrocodeinone)

but not including

Apomorphine (5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol)and its salts

Cyprenorphine (N-(cyclopropylmethyl)-6,7,8,14-tetrahydro-7α-(1-hydroxy-1-methylethyl)-6,14-endo-ethenonororipavine) and its salts

[Repealed, SOR/2016-239, s. 8]

Nalmefene (17-(cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diol)and its salts

Naloxone (4,5α-epoxy-3,14-dihydroxy-17-(2-propenyl)morphinan-6-one) and its salts

Naltrexone (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one)and its salts

Methylnaltrexone (17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium) and its salts

Naloxegol (4,5α-epoxy-6α-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propenyl)morphinan-3,14-diol) and its salts

Narcotine (6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo [4,5-g]isoquinolin-5-yl)-1(3H)-isobenzofuranone) and its salts

Papaverine (1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline) and itssalts

Poppy seed

Coca (Erythroxylum), its preparations, derivatives, alkaloids and salts, including:

Coca leaves

Cocaine (benzoylmethylecgonine)

Ecgonine (3-hydroxy-2-tropane carboxylic acid)

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 3/9

(4)

3

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

(23)

(24)

but not including

l-ioflupane

Phenylpiperidines, their intermediates, salts, derivatives and analogues and salts ofintermediates, derivatives and analogues, including:

Allylprodine (3-allyl-1-methyl-4-phenyl-4-piperidinol propionate)

Alphameprodine (α-3-ethyl-1-methyl-4-phenyl-4-piperidinol propionate)

Alphaprodine (α-1,3-dimethyl-4-phenyl-4-piperidinol propionate)

Anileridine (ethyl 1-[2-(p-aminophenyl) ethyl]-4-phenylpiperidine-4-carboxylate)

Betameprodine (ß-3-ethyl-1-methyl-4-phenyl-4-piperidinol propionate)

Betaprodine (ß-1,3-dimethyl-4-phenyl-4-piperidinol propionate)

Benzethidine (ethyl 1-(2-benzyloxyethyl)-4-phenylpiperidine-4-carboxylate)

Diphenoxylate (ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate)

Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate)

Etoxeridine (ethyl 1-[2-(2-hydroxyethoxy) ethyl]- 4-phenylpiperidine-4-carboxylate)

Furethidine (ethyl 1-(2-tetrahydrofurfuryloxyethyl)- 4-phenylpiperidine-4-carboxylate)

Hydroxypethidine (ethyl 4-(m-hydroxyphenyl)-1-methylpiperidine-4-carboxylate)

Ketobemidone (1-[4-(m-hydroxyphenyl)-1-methyl-4-piperidyl]-1-propanone)

Methylphenylisonipecotonitrile (4-cyano-1-methyl-4-phenylpiperidine)

Morpheridine (ethyl 1-(2-morpholinoethyl)-4- phenylpiperidine-4-carboxylate)

Norpethidine (ethyl 4-phenylpiperidine-4-carboxylate)

Pethidine (ethyl 1-methyl-4-phenylpiperidine-4-carboxylate)

Phenoperidine (ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate)

Piminodine (ethyl 1-[3-(phenylamino)propyl]-4-phenylpiperidine-4-carboxylate)

Properidine (isopropyl 1-methyl-4-phenylpiperidine-4- carboxylate)

Trimeperidine (1,2,5-trimethyl-4-phenyl-4-piperidinol propionate)

Pethidine Intermediate C (1-methyl-4-phenylpiperidine-4-carboxylate)

but not including

Carperidine (ethyl 1-(2-carbamylethyl)-4-phenylpiperidine-4-carboxylate) and itssalts

Oxpheneridine (ethyl 1-(2-hydroxy-2-phenylethyl)-4-phenylpiperidine-4-carboxylate)and its salts

123

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 4/9

4

(1)

(2)

(3)

(4)

5

(1)

(2)

(3)

(4)

(5)

(6)

(7)

6

(1)

(2)

(3)

(4)

(5)

(6)

(7)

7

(1)

(2)

(3)

8

(1)

Phenazepines, their salts, derivatives and salts of derivatives including:

Proheptazine (hexahydro-1,3-dimethyl-4-phenyl-1Hazepin-4-ol propionate)

but not including

Ethoheptazine (ethyl hexahydro-1-methyl-4-phenylazepine-4-carboxylate) and itssalts

Metethoheptazine (ethyl hexahydro-1,3-dimethyl-4-phenylazepine-4-carboxylate)and its salts

Metheptazine (methylhexahydro-1,2-dimethyl-4-phenylazepine-4-carboxylate) andits salts

Amidones, their intermediates, salts, derivatives and salts of intermediates andderivatives, including:

Dimethylaminodiphenylbutanonitrile (4-cyano-2-dimethylamino-4,4-diphenylbutane)

Dipipanone (4,4-diphenyl-6-piperidino-3-heptanone)

Isomethadone (6-dimethylamino-5-methyl-4,4-diphenyl-3-hexanone)

Methadone (6-dimethylamino-4,4-diphenyl-3-heptanone)

Normethadone (6-dimethylamino-4,4-diphenyl-3-hexanone)

Norpipanone (4,4-diphenyl-6-piperidino-3-hexanone)

Phenadoxone (6-morpholino-4,4-diphenyl-3-heptanone)

Methadols, their salts, derivatives and salts of derivatives, including:

Acetylmethadol (6-dimethylamino-4,4-diphenyl-3-heptanol acetate)

Alphacetylmethadol (α-6-dimethylamino-4,4-diphenyl-3-heptanol acetate)

Alphamethadol (α-6-dimethylamino-4,4-diphenyl-3-heptanol)

Betacetylmethadol (ß-6-dimethylamino-4,4-diphenyl-3-heptanol acetate)

Betamethadol (ß-6-dimethylamino-4,4-diphenyl-3-heptanol)

Dimepheptanol (6-dimethylamino-4,4-diphenyl-3-heptanol)

Noracymethadol (α-6-methylamino-4,4-diphenyl-3-heptanol acetate)

Phenalkoxams, their salts, derivatives and salts of derivatives, including

Dimenoxadol (dimethylaminoethyl 1-ethoxy-1,1-diphenylacetate)

Dioxaphetyl butyrate (ethyl 2,2-diphenyl-4-morpholinobutyrate)

Dextropropoxyphene ([S-(R*,S*)]-α-[2-(dimethylamino)-1-methylethyl]-α-phenylbenzeneethanol, propanoate ester)

Thiambutenes, their salts, derivatives and salts of derivatives, including:

Diethylthiambutene (N,N-diethyl-1-methyl-3,3-di-2-thienylallylamine)JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 5/9

(2)

(3)

9

(1)

(2)

(3)

(4)

10

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

(14)

(15)

11

Dimethylthiambutene (N,N,1-trimethyl-3,3-di-2-thienylallylamine)

Ethylmethylthiambutene (N-ethyl-N,1-dimethyl-3,3-di-2-thienylallylamine)

Moramides, their intermediates, salts, derivatives and salts of intermediates andderivatives, including:

Dextromoramide (d-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine)

Diphenylmorpholinoisovaleric acid (2-methyl-3-morpholino-1,1-diphenylpropionicacid)

Levomoramide (l-1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine)

Racemoramide (d,l-1-(3-methyl-4-morpholino-2,2- diphenylbutyryl)pyrrolidine)

Morphinans, their salts, derivatives and salts of derivatives, including:

Buprenorphine (17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol)

Drotebanol (6ß,14-dihydroxy-3,4-dimethoxy-17-methylmorphinan)

Levomethorphan (1-3-methoxy-17-methylmorphinan)

Levorphanol (1-3-hydroxy-17-methylmorphinan)

Levophenacylmorphan (1-3-hydroxy-17-phenacylmorphinan)

Norlevorphanol (1-3-hydroxymorphinan)

Phenomorphan (3-hydroxy-17-(2-phenylethyl)morphinan)

Racemethorphan (d,1-3-methoxy-17-methylmorphinan)

Racemorphan (d, l-3-hydroxy-N-methylmorphinan)

but not including

Dextromethorphan (d-1,2,3,9,10,10a-hexahydro-6-methoxy-11-methyl-4H-10,4a-iminoethanophenanthren) and its salts

Dextrorphan (d-1,2,3,9,10,10a-hexahydro-11-methyl-4H-10,4a-iminoethanophenanthren-6-ol) and its salts

Levallorphan (l-11-allyl-1,2,3,9,10,10a-hexahydro-4H-10,4a-iminoethanophenanthren-6-ol) and its salts

Levargorphan (l-11-propargyl-1,2,3,9,10,10a-hexahydro-4H-10,4a-iminoethanophenanthren-6-ol) and its salts

Butorphanol (l-N-cyclobutylmethyl-3,14-dihydroxymorphinan) and its salts

Nalbuphine (N-cyclobutylmethyl-4,5-epoxy-morphinan-3,6,14-triol) and its salts

Benzazocines, their salts, derivatives and salts of derivatives, including:

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 6/9

(1)

(2)

(3)

(4)

12

(1)

(2)

(3)

13

(1)

(2)

14

(1)

15

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

Phenazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl- 3-phenethyl-2,6-methano-3-benzazocin-8-ol)

Metazocine (1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-2,6-methano-3-benzazocin-8-ol)

Pentazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(3-methyl-2-butenyl)-2,6-methano-3-benzazocin-8-ol)

but not including

Cyclazocine (1,2,3,4,5,6-hexahydro-6,11-dimethyl-3-(cyclopropylmethyl)-2,6-methano-3-benzazocin-8-ol) and its salts

Ampromides, their salts, derivatives and salts of derivatives, including:

Diampromide (N-[2-(methylphenethylamino)propyl]propionanilide)

Phenampromide (N-(1-methyl-2-piperidino)ethyl)propionanilide)

Propiram (N-(1-methyl-2-piperidinoethyl)-N-2- pyridylpropionamide)

Benzimidazoles, their salts, derivatives and salts of derivatives, including:

Clonitazene (2-(p-chlorobenzyl)-1-diethylaminoethyl-5-nitrobenzimidazole)

Etonitazene (2-(p-ethoxybenzyl)-1-diethylaminoethyl-5- nitrobenzimidazole)

Phencyclidine (1-(1-phenylcyclohexyl)piperidine), its salts, derivatives and analoguesand salts of derivatives and analogues, including:

Ketamine (2-(2-chlorophenyl)-2- (methylamino)cyclohexanone)

Fentanyls, their salts, derivatives, and analogues and salts of derivatives andanalogues, including:

Acetyl-α-methylfentanyl (N-[1-(α-methylphenethyl)-4-piperidyl]acetanilide)

Alfentanil (N-[1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4- piperidyl]propionanilide)

Carfentanil (methyl 4-[(1-oxopropyl)phenylamino]-1- (2-phenethyl)-4-piperidinecarboxylate)

p-Fluorofentanyl (4′ fluoro-N-(1-phenethyl-4-piperidyl) propionanilide)

Fentanyl (N-(1-phenethyl-4-piperidyl)propionanilide)

ß-Hydroxyfentanyl (N-[1-(ß-hydroxyphenethyl)-4- piperidyl] propionanilide)

ß-Hydroxy-3-methylfentanyl (N-[1(ß-hydroxyphenethyl)-3-methyl-4-piperidyl]propionanilide)

α-Methylfentanyl (N-[1-(α-methylphenethyl)-4- piperidyl] propionanilide)

α-Methylthiofentanyl (N-[1-[1-methyl-2-(2-thienyl)ethyl]-4-piperidyl] propionanilide)

3-Methylfentanyl (N-(3-methyl-1-phenethyl-4-piperidyl) propionanilide)

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 7/9

(11)

(11.1)

(12)

(13)

16

17

18

(1)

(i)

(ii)

(iii)

(iv)

(v)

(2)

(i)

(ii)

(iii)

(iv)

(v)

3-Methylthiofentanyl (N-[3-methyl-1-[2-(2-thienyl)ethyl]-4-piperidyl] propionanilide)

Remifentanil (dimethyl 4-carboxy-4-(N-phenylpropionamido)-1-piperidinepropionate)

Sufentanil (N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4- piperidyl] propionanilide)

Thiofentanyl (N-[1-[2-(2-thienyl)ethyl]-4-piperidyl] propionanilide)

Tilidine (ethyl 2-(dimethylamino)-1-phenyl-3-cyclohexene-1-carboxylate), its salts,derivatives and salts of derivatives

[Repealed, SOR/2018-147, s. 28]

Synthetic cannabinoid receptor type 1 agonists, their salts, derivatives, isomers, andsalts of derivatives and isomers — with the exception of ((3S)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone(WIN 55,212-3) and its salts — including those that fall within the following corechemical structure classes:

Any substance that has a 2-(cyclohexyl)phenol structure with substitution at the 1-position of the benzene ring by a hydroxy, ether or ester group and furthersubstituted at the 5-position of the benzene ring, whether or not further substitutedon the benzene ring to any extent, and substituted at the 3’-position of thecyclohexyl ring by an alkyl, carbonyl, hydroxyl, ether or ester, and whether or notfurther substituted on the cyclohexyl ring to any extent, including

Nabilone ((±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one)

Parahexyl (3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-ol)

3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol (DMHP)

5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP55,940)

5-(1,1-dimethylheptyl)-2-(3-hydroxycyclohexyl)phenol (CP 47,497)

Any substance that has a 3-(1-naphthoyl)indole structure with substitution at thenitrogen atom of the indole ring, whether or not further substituted on the indole ringto any extent and whether or not substituted on the naphthyl ring to any extent,including

1-pentyl-3-(1-naphthoyl)indole (JWH-018)

1-butyl-3-(1-naphthoyl)indole (JWH-073)

1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)

1-hexyl-3-(1-naphthoyl)indole (JWH-019)

1-(4-pentenyl)-3-(1-naphthoyl)indole (JWH-022)JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 8/9

(vi)

(vii)

(viii)

(ix)

(x)

(xi)

(xii)

(xiii)

(xiv)

(xv)

(3)

(i)

(4)

(i)

(ii)

(iii)

(5)

(i)

(6)

(i)

(ii)

1-butyl-3-(4-methoxy-1-naphthoyl)indole (JWH-080)

1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081)

1-(2-morpholin-4-ylethyl)-3-(1-naphthoyl)indole (JWH-200)

1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210)

1-pentyl-3-(2-methoxy-1-naphthoyl)indole (JWH-267)

1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220)

1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201)

1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (MAM-2201)

1-(5-fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201)

((3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone (WIN 55,212-2)

Any substance that has a 3-(1-naphthoyl)pyrrole structure with substitution at thenitrogen atom of the pyrrole ring, whether or not further substituted on the pyrrolering to any extent and whether or not substituted on the naphthyl ring to any extent,including

1-pentyl-5-(2-fluorophenyl)-3-(1-naphthoyl)pyrrole (JWH-307)

Any substance that has a 3-phenylacetylindole structure with substitution at thenitrogen atom of the indole ring, whether or not further substituted on the indole ringto any extent and whether or not substituted on the phenyl ring to any extent,including

1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)

1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251)

1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302)

Any substance that has a 3-benzoylindole structure with substitution at the nitrogenatom of the indole ring, whether or not further substituted on the indole ring to anyextent and whether or not substituted on the phenyl ring to any extent, including

1-(1-methylpiperidin-2-ylmethyl)-3-(2-iodobenzoyl)indole (AM-2233)

Any substance that has a 3-methanone(cyclopropyl)indole structure with substitutionat the nitrogen atom of the indole ring, whether or not further substituted on theindole ring to any extent and whether or not substituted on the cyclopropyl ring toany extent, including

(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (UR-144)

(1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (5F-UR-144)

JE022020

1/6/2020 Narcotic Control Regulations

https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.%2C_c._1041/page-14.html#h-10 9/9

(iii)

(7)

(i)

(ii)

(8)

(i)

(ii)

(iii)

(iv)

(9)

(i)

(ii)

18.1

(1-(2-(4-morpholinyl)ethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone (A-796,260)

Any substance that has a quinolin-8-yl 1H-indole-3-carboxylate structure withsubstitution at the nitrogen atom of the indole ring, whether or not further substitutedon the indole ring to any extent and whether or not substituted on the quinolin-8-ylring to any extent, including

1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22)

1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5F-PB-22)

Any substance that has a 3-carboxamideindazole structure with substitution at thenitrogen atom of the indazole ring, whether or not further substituted on the indazolering to any extent and whether or not substituted at the carboxamide group to anyextent, including

N-(adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide (AKB48)

N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AKB48)

N-(1-(aminocarbonyl)-2-methylpropyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA)

Any substance that has a 3-carboxamideindole structure with substitution at thenitrogen atom of the indole ring, whether or not further substituted on the indole ringto any extent and whether or not substituted at the carboxamide group to any extent,including

N-(adamantan-1-yl)-1-fluoropentylindole-3-carboxamide (STS-135)

N-(adamantan-1-yl)-1-pentylindole-3-carboxamide (APICA)

Tapentadol (3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol), its salts,derivatives and isomers and salts of derivatives and isomers

SOR/97-227, s. 5; SOR/98-158, s. 1; SOR/99-372, ss. 1, 2; SOR/2000-244, s. 1(E); SOR/2003-33, s. 1;SOR/2005-272, s. 1; SOR/2013-172, s. 9; SOR/2015-189, s. 1; SOR/2015-191, ss. 1, 2; SOR/2016-230, s. 279;SOR/2016-239, s. 8; SOR/2017-12, ss. 5 to 9; SOR/2017-276, s. 1; SOR/2018-69, ss. 72, 73, 74(F); SOR/2018-147, s. 28.

Date modified:2019-12-13

JE022020

1/6/2020 Food and Drug Regulations

https://laws.justice.gc.ca/eng/regulations/c.r.c.,_c._870/page-166.html#h-579949 1/5

1

(1)

(2)

(3)

2

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

3

4

5

6

7

8

9

Food and Drug Regulations (C.R.C. (Consolidated Regulations of Canada), c. 870)Regulations are current to 2019-12-03 and last amended on 2019-06-17.

SCHEDULE(Sections G.01.001 and G.01.004, subsection G.02.014(3), subparagraph G.02.025(1)(b)(iii), subsections G.02.025(3.2) and (4) and G.03.001(3), paragraph G.03.006(a), sectionG.03.007 and subsection G.05.001(4))

PART I

Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives,isomers and analogues, excluding those substances set out in item 1 of Part I of theschedule to Part J but including:

amphetamine (α-methylbenzeneethanamine)

methamphetamine (N,α-dimethylbenzeneethanamine)

Benzphetamine (N-benzyl-N,α-dimethylbenzeneethanamine)

Methylphenidate (methyl 2-phenyl-2-(piperidin-2-yl)acetate), its salts, derivatives,isomers and analogues and salts of derivatives, isomers and analogues, including:

Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate)

Isopropylphenidate (isopropyl 2-phenyl-2-(piperidin-2-yl)acetate)

Propylphenidate (propyl 2-phenyl-2-(piperidin-2-yl)acetate)

3,4-Dichloromethylphenidate (methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate)

4-Methylmethylphenidate (methyl 2-(4-methylphenyl)-2-(piperidin-2-yl)acetate)

4-Fluoromethylphenidate (methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate)

Methylnaphthidate (methyl 2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate)

Ethylnaphthidate (ethyl 2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate)

Methaqualone (2-methyl-3-(2-methylphenyl)-4(3H)quinazolinone) and any salt thereof

Phendimetrazine (d-3,4-dimethyl-2-phenylmorpholine) and any salt thereof

Phenmetrazine (3-methyl-2-phenylmorpholine) and any salt thereof

Pentobarbital (5-ethyl-5-(1-methylbutyl)barbituric acid)

Secobarbital (5-allyl-5-(1-methylbutyl)barbituric acid)

4-hydroxybutanoic acid (GHB) and any salt thereof

Aminorex (5-phenyl-4,5-dihydro-1,3-oxazol-2-amine), its salts, derivatives, isomers andanalogues and salts of derivatives, isomers and analogues, including

JE022020

1/6/2020 Food and Drug Regulations

https://laws.justice.gc.ca/eng/regulations/c.r.c.,_c._870/page-166.html#h-579949 2/5

(1)

(2)

10

11

12

13

14

15

16

17

1

(1)

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

4-Methylaminorex (4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine)

4,4’-Dimethylaminorex (4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine)

Fenetylline (d,l-3,7-dihydro-1,3-dimethyl-7-(2-[(1-methyl-2-phenethyl)amino]ethyl)-1H-purine-2,6-dione) and any salt thereof

Glutethimide (2-ethyl-2-phenylglutarimide)

Lefetamine ((-)-N,N-dimethyl-α-phenylbenzeneethanamine), its salts, derivatives andisomers and salts of derivatives and isomers

Mecloqualone (2-methyl-3-(2-chlorophenyl)-4(3H)-quinazolinone) and any salt thereof

Mesocarb (3-(α-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine) and any saltthereof

Pemoline (2-amino-5-phenyl-oxazolin-4-one) and any salt thereof

Zipeprol (4-(2-methoxy-2-phenylethyl)-α-(methoxyphenylmethyl)-1-piperazineethanol)and any salt thereof

Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid)and any salt thereof

PART II

Barbiturates, their salts and derivatives, excluding the substances set out in items 6 and7 of Part I of this schedule, as well as barbituric acid (2,4,6(1H,3H,5H)-pyrimidinetrione)and its salts and 1,3-dimethylbarbituric acid (1,3-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione) and its salts, but including

Allobarbital (5,5-diallylbarbituric acid)

Alphenal (5-allyl-5-phenylbarbituric acid)

Amobarbital (5-ethyl-5-(3-methylbutyl)barbituric acid)

Aprobarbital (5-allyl-5-isopropylbarbituric acid)

Barbital (5,5-diethylbarbituric acid)

[Repealed, SOR/2017-12, s. 1]

Butabarbital (5-sec-butyl-5-ethylbarbituric acid)

Butalbital (5-allyl-5-isobutylbarbituric acid)

Butallylonal (5-(2-bromoallyl)-5-sec-butylbarbituric acid)

Butethal (5-butyl-5-ethylbarbituric acid)

Cyclobarbital (5-(1-cyclohexen-1-yl)-5-ethylbarbituric acid)

Cyclopal (5-allyl-5-(2-cyclopenten-1-yl)barbituric acid)

JE022020

1/6/2020 Food and Drug Regulations

https://laws.justice.gc.ca/eng/regulations/c.r.c.,_c._870/page-166.html#h-579949 3/5

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

(23)

(24)

(25)

(26)

2

(1)

(2)

(3)

(4)

3

4

5

6

7

8

1

(1)

(2)

(3)

(4)

Heptabarbital (5-(1-cyclohepten-1-yl)-5-ethylbarbituric acid)

Hexethal (5-ethyl-5-hexylbarbituric acid)

Hexobarbital (5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid)

Mephobarbital (5-ethyl-1-methyl-5-phenylbarbituric acid)

Methabarbital (5,5-diethyl-1-methylbarbituric acid)

Methylphenobarbital (5-ethyl-1-methyl-5-phenylbarbituric acid)

Propallylonal (5-(2-bromoallyl)-5-isopropyl-barbituric acid)

Phenobarbital (5-ethyl-5-phenylbarbituric acid)

Probarbital (5-ethyl-5-isopropylbarbituric acid)

Phenylmethylbarbituric Acid (5-methyl-5-phenylbarbituric acid)

Sigmodal(5-(2-bromoallyl)-5-(1-methylbutyl)- barbituric acid)

Talbutal (5-allyl-5-sec-butylbarbituric acid)

Vinbarbital (5-ethyl-5-(1-methyl-1-butenyl)barbituric acid)

Vinylbital (5-(1-methylbutyl)-5-vinylbarbituric acid)

Thiobarbiturates, their salts and derivatives, including:

Thialbarbital (5-allyl-5-(2-cyclohexen-1-yl)-2-thiobarbituric acid)

Thiamylal (5-allyl-5-(1-methylbutyl)-2-thiobarbituric acid)

Thiobarbituric Acid (2-thiobarbituric acid)

Thiopental(5-ethyl-5-(1-methylbutyl)-2- thiobarbituric acid)

Chlorphentermine (1-(p-chlorophenyl)-2-methyl-2-aminopropane) and any salt thereof

Diethylpropion (2-(diethylamino)propiophenone) and any salt thereof

Phentermine (α,α-dimethylbenzeneethanamine) and any salt thereof

Butorphanol (1-N-cyclobutylmethyl-3,14-dihydroxymorphinan) and its salts

Nalbuphine (N-cyclobutylmethyl-4,5-epoxy-morphinan-3,6,14-triol) and any salt thereof

Pyrovalerone (4′-methyl-2-(1-pyrrolidinyl)valerophenone) and any salt thereof

PART III

Anabolic steroids and their derivatives, including:

Androisoxazole (17ß-hydroxy-17α-methylandrostano[3,2-c]isoxazole)

Androstanolone (17ß-hydroxy-5α-androstan-3-one)

Androstenediol (androst-5-ene-3ß,17ß-diol)

Bolandiol (estr-4-ene-3b,17ß-diol)JE022020

1/6/2020 Food and Drug Regulations

https://laws.justice.gc.ca/eng/regulations/c.r.c.,_c._870/page-166.html#h-579949 4/5

(5)

(6)

(7)

(8)

(9)

(10)

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

(23)

(24)

(25)

(26)

(27)

(28)

(29)

(30)

(31)

(32)

(33)

(34)

(35)

Bolasterone (17ß-hydroxy-7α,17-dimethylandrost-4-en-3-one)

Bolazine (17ß-hydroxy-2α-methyl-5α-androstan-3-one azine)

Boldenone (17ß-hydroxyandrosta-1,4-dien-3-one)

Bolenol (19-nor-17α-pregn-5-en-17-ol)

Calusterone (17ß-hydroxy-7b,17-dimethylandrost-4-en-3-one)

Clostebol (4-chloro-17ß-hydroxyandrost-4-en-3-one)

Drostanolone (17ß-hydroxy-2α-methyl-5α-androstan-3-one)

Enestebol (4,17ß-dihydroxy-17-methylandrosta-1,4-dien-3-one)

Epitiostanol (2α, 3α-epithio-5α-androstan-17ß-ol)

Ethylestrenol (19-nor-17α-pregn-4-en-17-ol)

4-Hydroxy-19-nor testosterone

Fluoxymesterone (9-fluoro-11ß,17ß-dihydroxy — 17-methylandrost-4-en-3-one)

Formebolone (11α,17ß-dihydroxy-17-methyl-3-oxoandrosta-1,4-dien-2-carboxaldehyde)

Furazabol (17-methyl-5α-androstano[2,3-c]furazan-17ß-ol)

Mebolazine (17ß-hydroxy-2α,17-dimethyl-5α-androstan-3-one azine)

Mesabolone (17ß-[(1-methoxycyclohexyl)oxy]-5α-androst-1-en-3-one)

Mesterolone (17ß-hydroxy-1α-methyl-5α-androstan-3-one)

Metandienone (17ß-hydroxy-17-methylandrosta-1,4-dien-3-one)

Metenolone (17ß-hydroxy-1-methyl-5α-androst-1-en-3-one)

Methandriol (17α-methylandrost-5-ene-3ß,17ß-diol)

Methyltestosterone (17ß-hydroxy-17-methyl-androst-4-en-3-one)

Metribolone (17ß-hydroxy-17-methylestra-4,9,11-trien-3-one)

Mibolerone (17ß-hydroxy-7α,17-dimethylestr-4-en-3-one)

Nandrolone (17ß-hydroxyestr-4-en-3-one)

Norboletone (13-ethyl-17ß-hydroxy-18,19-dinorpregn-4-en-3-one)

Norclostebol (4-chloro-17ß-hydroxyestr-4-en-3-one)

Norethandrolone (17α-ethyl-17ß-hydroxyestr-4-en-3-one)

Oxabolone (4,17ß-dihydroxyestr-4-en-3-one)

Oxandrolone (17ß-hydroxy-17-methyl-2-oxa-5α-androstan-3-one)

Oxymesterone (4,17ß-dihydroxy-17-methylandrost-4-en-3-one)

Oxymetholone (17ß-hydroxy-2-(hydroxymethylene)-17-methyl-5α-androstan-3-one)JE022020

1/6/2020 Food and Drug Regulations

https://laws.justice.gc.ca/eng/regulations/c.r.c.,_c._870/page-166.html#h-579949 5/5

(36)

(37)

(38)

(39)

(40)

(41)

(42)

(43)

2

Prasterone (3ß-hydroxyandrost-5-en-17-one)

Quinbolone (17ß-(1-cyclopenten-1-yloxy)androsta-1,4-dien-3-one)

Stanozolol (17ß-hydroxy-17-methyl-5α-androstano[3,2-c]pyrazole)

Stenbolone (17ß-hydroxy-2-methyl-5α-androst-1-en-3-one)

Testosterone (17ß-hydroxyandrost-4-en-3-one)

Tibolone ((7α,17α)-17-hydroxy-7-methyl-19-norpregn-5(10)en-20-yn-3-one)

Tiomesterone (1α,7α-bis(acetylthio)-17ß-hydroxy-17-methylandrost-4-en-3-one)

Trenbolone (17ß-hydroxyestra-4,9,11-trien-3-one)

Zeranol (3,4,5,6,7,8,9,10,11,12-decahydro-7,14,16-trihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1-one)

SOR/78-427, s. 10; SOR/79-753, s. 1; SOR/81-84, s. 1; SOR/85-550, s. 14(F); SOR/86-678, s. 1; SOR/89-381,s. 1; SOR/92-386, s. 3; SOR/97-228, s. 21; SOR/99-425, s. 1; SOR/2003-34, ss. 2, 3; SOR/2003-413, s. 2;SOR/2015-210, s. 1; SOR/2016-106, s. 1; SOR/2017-12, ss. 1, 2(E); SOR/2017-43, s. 1; SOR/2017-250, s. 1.

Date modified:2019-12-13

JE022020

1/6/2020 Benzodiazepines and Other Targeted Substances Regulations

https://laws.justice.gc.ca/eng/regulations/SOR-2000-217/page-15.html#h-661317 1/3

Benzodiazepines and Other Targeted Substances Regulations (SOR (Statutory Orders andRegulations)/2000-217)

Regulations are current to 2019-12-03 and last amended on 2018-10-17.

SCHEDULE 2(Subsection 1(1))

Specified Names of Targeted Substances

Item

Column 1 Column 2

Specified Name Chemical Name

1 Alprazolam 8-chloro-1-methyl-6-phenyl-4H — s-triazolo[4,3-a][1,4]benzodiazepine

2 Bromazepam 7-bromo-1,3-dihydro-5-(2-pyridyl) — 2H-1,4-benzodiazepin-2-one

3 Brotizolam 2-bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-s-triazolo[4,3-a][1,4]diazepine

4 Camazepam 7-chloro-1,3-dihydro-3-(N,N-dimethylcarbamoyl) — 1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one

5 Chlordiazepoxide 7-chloro-2-(methylamino)-5 — phenyl-3H-1,4-benzodiazepine-4-oxide

6 Clobazam 7-chloro-1-methyl-5-phenyl-1H-1,5 — benzodiazepine-2,4(3H,5H)-dione

7 Clonazepam 5-(o-chlorophenyl)-1,3-dihydro-7 — nitro-2H-1,4-benzodiazepin-2-one

8 Clorazepate 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid

9 Cloxazolam 10-chloro-11b-(o-chlorophenyl)-2,-3,7,11b-tetrahydrooxazolo[3,2-d][1,4]benzodiazepin-6[5H]-one

10 Delorazepam 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-2H-1,-4-benzodiazepin-2-one

11 Diazepam 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one

12 Estazolam 8-chloro-6-phenyl-4H-s-triazolo[4,3-a] — [1,4]benzodiazepine

13 Ethyl Loflazepate ethyl 7-chloro-5-(o-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,-4-benzodiazepine-3-carboxylate

JE022020

1/6/2020 Benzodiazepines and Other Targeted Substances Regulations

https://laws.justice.gc.ca/eng/regulations/SOR-2000-217/page-15.html#h-661317 2/3

Item

Column 1 Column 2

Specified Name Chemical Name

14 Fludiazepam 7-chloro-5-(o-fluorophenyl)-1,3-di-hydro-1-methyl-2H-1,4-benzodiazepin-2-one

15 Flurazepam 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one

16 Halazepam 7-chloro-1,3-dihydro-5-phenyl-1-(2,2,-2-trifluoroethyl)-2H-1,4-benzodiazepin-2-one

17 Haloxazolam 10-bromo-11b-(o-fluorophenyl)-2,3,7,11b-tetrahydro-oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one

18 Ketazolam 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]-oxazino-[3,2-d][1,4]benzodiazepine-4,7(6H)-dione

19 Loprazolam 6-(o-chlorophenyl)-2,4-dihydro-2-[(4--methyl-1-piperazinyl)methylene]-8-nitro-1H-imidazo[1,2-a][1,4]-benzodiazepin-1-one

20 Lorazepam 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one

21 Lormetazepam 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one

22 Medazepam 7-chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine

23 Midazolam 8-chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine

24 Nimetazepam 1,3-dihydro-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one

25 Nitrazepam 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one

26 Nordazepam 7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one

27 Oxazepam 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one

28 Oxazolam 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyloxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one

29 Pinazepam 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-2H-1,-4-benzodiazepin-2-one

30 Prazepam 7-chloro-1-(cyclopropylmethyl)-1,3-di-hydro-5-phenyl-2H-1,4-benzodiazepin-2-one

31 Quazepam 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-thione

JE022020

1/6/2020 Benzodiazepines and Other Targeted Substances Regulations

https://laws.justice.gc.ca/eng/regulations/SOR-2000-217/page-15.html#h-661317 3/3

Item

Column 1 Column 2

Specified Name Chemical Name

32 Temazepam 7-chloro-1,3-dihydro-3-hydroxy-1methyl-5-phenyl-2H-1,4-benzodiazepin-2-one

33 Tetrazepam 7-chloro-5-(cyclohexen-1-yl)-1,3-di-hydro-1-methyl-2H-1,4-benzodiazepin-2-one

34 Triazolam 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo-[4,3-a][1,4]benzodiazepine

35 Clotiazepam 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2-H-thieno[2,3-e]-1,4-diazepin-2-one

36 Ethchlorvynol ethyl-2-chlorovinyl ethynyl carbinol

37 Ethinamate 1-ethynylcyclohexanol carbamate

38 Fencamfamin d,l-N-ethyl-3-phenylbicyclo[2,2,1]-heptan-2-amine

39 Fenproporex d,l-3-[(α-methylphenethyl)amino]propionitrile

40 Flunitrazepam 3(5-(o-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one

41 Mazindol 5-(p-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol

42 Mefenorex d,l-N-(3-chloropropyl)-α-methylbenzene-ethanamine

43 Meprobamate 2-methyl-2-propyl-1,3-propanedioldicarbamate

44 Methyprylon 3,3-diethyl-5-methyl-2,4-piperidinedione

45 Pipradrol α,α-diphenyl-2-piperidinemethanol

46 Zolpidem N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide

SOR/2003-38, s. 4; SOR/2017-12, s. 11.

Date modified:2019-12-13

JE022020